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Amyotrophic lateral sclerosis (ALS) is a devastating disease.  Currently, there is 
no cure for this disease, and effective treatment strategies are greatly needed.  Calpain 
activation plays a major role in the motor neuron degeneration that causes ALS. 
Therefore, therapeutic strategies can inhibit calpain activity in the central nervous system 
(CNS) have great clinical potential.  The calpain inhibitors AK295 and MDL-28170 have 
been demonstrated to be neuroprotective in animal models of neurological injury, and 
should have great potential to treat ALS; however delivery problems have hindered their 
clinical success. Although many delivery strategies have been developed for overcoming 
CNS barriers, none of them have the properties needed for treating ALS with AK295.  
Therefore, development of a new strategy that can locally deliver the calpain inhibitors to 
the central nervous system could significantly improve the treatment of ALS.  The 
objectives of my thesis research were (1) to develop high molecular weight polyketals 
that provide sustained release properties for hydrophobic molecules, (2) to formulate 
calpain inhibitor-encapsulated polyketal microparticles which have a release half life of 
one month in vitro, (3) and to evaluate the performance of polyketal microparticles for 
delivering calpain inhibitors to the spinal cord in vivo. 
The first two specific aims focused on developing a biodegradable polymeric 
delivery system which has the sustained release properties needed for calpain inhibitor 
delivery.  In the first specific aim, we developed a polyketal microparticle delivery 
system which has a sustained release profile of one month for hydrophobic dye, as a 





a series of high molecular weight polyketal polymers, which can enhance the 
encapsulation efficiency of calpain inhibitors and improve their structural stability of 
polyketal microparticles.  The goal of the second specific aim was to develop a polyketal 
microparticle delivery system for the calpain inhibitors, AK295 and MDL-28170, and 
evaluate their in vitro release profiles and bioactivities.  AK295- and MDL-28170-loaded 
polyketal microparticles (AK-PKMs and MDL-PKMs) were prepared by a single 
emulsion solvent evaporation procedure.  The results of calpain assay showed that both 
AK-PKMs and MDL-PKMs maintain most of their inhibitory activities even after the 
robust emulsion process.  The in vitro release profile of MDL-28170 in MDL-PKMs 
showed 50% of the drug was released in the first 30 days. 
  In the third specific aim, we demonstrated that polyketal microparticles can be 
safely delivered to the spinal cord.  Experiments using dye-encapsulated microparticles 
showed that polyketal microparticles (1-2 μm diameter) are not easily cleared in the 
neutral physiological environment and can have potential to continuously release drug 
from the injection sites in the spinal cord.  The efficacy of calpain inhibitor-encapsulated 
PKMs were studied by evaluation the behavior and survival of SOD1G93A rats, a genetic 
rat model for ALS.  We observed the trend toward improvements in grip strength and 
rotarod performance in the first two months from the AK-PKMs treated group, however, 
there was no statistical differences between calpain inhibitor treated group with saline 
control.  In summary, our data show that polyketal microparticles have considerable 
potential as delivery system for calpain inhibitor for the treatment of ALS, however, 




1.1. Background and Motivation 
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease 
that causes rapid loss of motor neurons and leads to muscular atrophy, respiratory failure 
and eventually death (Sejvar, Holman et al. 2005).  In the United States alone, 
approximately 5,600 new cases of ALS are expected to be diagnosed each year, and the 
life expectancy of an ALS patient averages two to five years from the time of diagnosis.  
Although the disease was first identified 140 years ago, the exact cause of motor neuron 
loss in ALS remains unknown.  Currently, riluzole (Rilutek®) is the only drug treatment 
for ALS approved by the Food and Drug Administration (FDA).  However, the drug only 
slows progression of ALS rather than curing the disease (Bruijn, Miller et al. 2004; 
Nirmalananthan and Greensmith 2005).  Therefore, new treatment options are greatly 
needed for this devastating disease. 
Calpain activation is a known important mechanism of motor neuron degeneration 
in ALS (Fischer, Culver et al. 2004), and therefore therapeutic strategies that can inhibit 
calpain activity specifically in the CNS have clinical potential.  Calpain inhibitors have 
been demonstrated to be neuroprotective in animal models of neurological injury, and 
should have great potential to treat ALS; however delivery problems have hindered their 
clinical success.  For example, AK295 is a hydrophobic calpain inhibitor, which shows 
great drug properties but has low efficacy in vivo, due to issues with crossing the CNS 
barriers.  Thus, there is a great need to find a safe and effective CNS drug delivery 
system that can translate these experimental strategies into clinical therapies. 
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Drug delivery to the CNS has been particularly inefficient, largely due to the 
barriers in the CNS.  Only some small hydrophobic agents (< 500 Daltons) can penetrate 
these barriers (Lesniak and Brem 2004).  To achieve therapeutic levels of drug in the 
CNS, the drug must be administered systemically at high dosage, which leads to serious 
side effects.  One possible way to minimize systemic side effects is to administer the drug 
directly into the CNS.  
Many strategies have been developed to improve the safety and efficiency of local 
drug delivery, such as implantable catheter pump systems and implantable polymeric 
drug delivery systems (Gill, Patel et al. 2003).  Direct drug infusion by minipumps can 
precisely control the dosage at the site of interest; however, there are still some flaws 
limiting the success of this type of drug delivery systems, such as infection, catheter 
obstruction and patient discomfort.  Implantation of drug-containing biodegradable 
devices such as microparticles can deliver the highest local drug concentration (Kirik, 
Georgievska et al. 2004; Clavreul, Sindji et al. 2006), however, despite their attractive 
features; microparticles have not been used extensively for the treatment of ALS or other 
neurodegenerative diseases. This is primarily because currently used biomaterials for 
microparticle-based drug delivery are predominantly based on polyesters such as 
poly(lactic-co-glycolic acid) (PLGA), which degrade into acidic products that may 
destroy the encapsulated therapeutic agents and cause an inflammatory response 
(Shenderova, Burke et al. 1999; Fu, Pack et al. 2000; Tamber, Johansen et al. 2005). 
Polyketals are new biodegradable polymers which degrade into the neutral 
products, acetone and diols (Heffernan and Murthy 2005; Lee, Yang et al. 2007; Yang, 
Bhide et al. 2008).  Microparticles formulated from polyketals have shown promise as 
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drug delivery vehicles for the treatment of ALS because they have excellent 
biocompatibility and do not generate inflammatory acid degradation products as do 
polyester-based biomaterials (Sy, Seshadri et al. 2008).  In addition, polyketals provide a 
wide range of degradation rates, ranging from weeks to months at pH 7.4, depending on 
their compositions. Drug release rates from polyketal microparticles can be controlled by 
manipulation of the hydrophobicity of the polymers.  Due to these advantages, 
microparticles formulated from polyketals show promise to enhance the treatment of 
inflammatory diseases (Sy, Seshadri et al. 2008; Yang, Bhide et al. 2008). 
However, polyketal-based delivery systems have lower drug loading efficiency 
than the delivery systems based on other biodegradable polymers, such as PLGA and 
polyanhydride.  This is possibly due to the low molecular weight of current polyketals.  
Also, particles formulated from low molecular weight polyketals have less structure 
stability and tend to collapse under high speed centrifugation.  Given these limitations of 
current polyketal polymers, a new synthetic methodology which can increase the 
molecular weight of polyketals and expand their applications is needed. 
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1.2 Research Objectives and Specific Aims 
Calpain activation is an important mechanism of motor neuron degeneration in 
ALS, and therapeutic strategies that can inhibit calpain activity in the central nervous 
system (CNS) have great clinical potential.  Calpain inhibitors have been demonstrated to 
be neuroprotective in animal models of neurological injury, and have great potential to 
treat ALS; however delivery problems have hindered their clinical success.  AK295 is a 
hydrophobic calpain inhibitor, which shows great drug properties for treating ALS but 
has low efficacy in vivo, due to the barriers in the CNS.  Although many delivery 
strategies have been developed for overcoming CNS barriers, none of them have 
properties needed for treating ALS with AK295.  Therefore, development of a new 
strategy that can locally deliver calpain inhibitor to the central nervous system could 


















Scheme 1.1 Polyketal-based drug delivery system for ALS treatment.  Calpain 
inhibitors (AK295 and MDL-28170) were encapsulated within polyketal microparticles 
and injected into the spinal cord of rats.  The microparticles are designed to release 
AK295 slowly into the spinal cord over a period of weeks to months. 
 
The goal of this research was to develop an injectable polyketal microparticle 
delivery system which can generate a several micromolar concentration of calpain 
inhibitor in the spinal cord for two months after a single injection (Scheme 1.1). 
The objectives of my thesis research were (1) to develop high molecular weight 
polyketal microparticles that provide sustained release properties for hydrophobic 
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molecules, (2) to formulate calpain inhibitor-encapsulated polyketal microparticles which 
have a release half life of 1 month in vitro, (3) to evaluate the performance of polyketal 
microparticles for delivering calpain inhibitors to the spinal cord in vivo.  The central 
hypothesis of this research is that: a direct injection of calpain inhibitor-polyketal 
microparticles into the spinal cord will generate several micromolar concentration of 
calpain inhibitor in a two month period. The central hypothesis of this thesis was tested 
by completing the following aims. 
Specific Aim 1: Formulate hydrophobic dye-encapsulated PKMs which have a 
release half-life of 1 month in vitro.  
Hypothesis 1: We hypothesize that (1) high molecular weight polyketals can 
enhance drug loading efficiency, (2) that the drug release rate from PKMs can be 
controlled by manipulating their sizes.  
In this aim, high molecular weight polyketals were synthesized via a new 
methodology using 2,2-diethoxypropane (DEP), a ketal with a high boiling point.  The 
reactions were optimized with regards to the reaction temperature, duration and fine-
tuned by an extra volume of ketals.  The resulting high molecular weight polyketals were 
characterized by gel permeation chromatography (GPC) and nuclear magnetic resonance 
(NMR) spectroscopy, and their pH-sensitive degradation were demonstrated by NMR.  
One of the high molecular weight polyketals, PCADKe, had lowest hydrolysis rate of the 
polyketals, thus microparticles formulated from PCADKe have the potential for sustained 
delivery of hydrophobic compounds at pH 7.4.  The release kinetics of polyketal 
microparticles (PKMs) were optimized by using a fluorescent dye, DiI as a model 
compound for calpain inhibitors, due to a similar hydrophobicity between DiI and calpain 
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inhibitors (AK295 and MDL-28170), and can be measured by fluorescence spectrometry. 
Various formulations and sizes of polyketal microparticles (PKMs) were prepared and 
characterized to optimize their release rates.  
Specific Aim 2: Formulate calpain inhibitor-encapsulated PKMs which have a 
release half-life of 1 month in vitro.  
Hypothesis 2: We hypothesize that calpain inhibitor-encapsulated microparticles 
(AK-PKMs and MDL-PKMs) can preserve the activity of calpain inhibitors and have a 
release half-life of 1 month.   
In this aim, PKMs which contain the calpain inhibitors (AK295 or MDL-28170) 
were fabricated, using formulation procedures developed in Aim 1.  The size of AK295 
encapsulated PCADKe microparticles (AK-PKMs) and MDL-28170 encapsulated 
PCADKe microparticles (MDL-PKMs) were characterized by scanning electron 
microscopy (SEM).  The encapsulation efficiency of AK295 in AK-PKMs was measured 
by liquid chromatography-mass spectrometry (LC-MS).  The encapsulation efficiency 
and in vitro release profile of MDL-28170 in MDL-PKMs were measured by reverse 
phase high performance liquid chromatography (HPLC).  The inhibitory activity of 
AK295 and MDL-28170 released from microparticles were measured by a modified in 
vitro calpain assay. 
Specific Aim 3: Deliver calpain inhibitor-encapsulated microparticles to the 
spinal cord and evaluate their in vivo efficacy. 
Hypothesis 3: We hypothesize that polyketal microparticles will deliver several 
micromolar concentration of calpain inhibitor to the spinal cord for two months after an 
intraspinal cord injection.  
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In Specific Aim 3, we investigated the in vivo performance of PCADKe 
microparticles.  The dye encapsulated PKMs (Nile Red PKMs, DiI-PKMs and coumarin 
6 PKMs) formulated in Aim 1 were used to study the fate of the polyketal microparticles 
after intraspinal cord injection.  The distribution of the microparticles was measured by 
fluorescence microscopy.  The AK-PKMs and MDL-PKMs formulated in Aim 2 were 
used to investigate the in vivo activity of calpain inhibitors in the spinal cord tissue.  In 
this specific aim, either AK-PKMs (n = 8), MDL-PKMs (n = 8), or PBS (n = 6) were 
injected into the lumbar enlargement, L1-L2, of SOD1G93A rats, a genetic rat model for 
ALS.  For each SOD1G93A rats, 5 μL of 50 mg/mL AK-PKMs, 50 mg/mL MDL-PKMs, 
or PBS was injected into both hemispheres of the spinal cord at 70 days, which precedes 
symptom onset.  Disease progression was monitored by weekly assessment of weight 
loss, grip strength, rotarod performance, and ALS motor score.  A survival curve of the 
ALS animals was generated using Kaplan-Meier method.  
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1.3 Review of Relevant Literature 
Calpain inhibitors have great potential to treat ALS 
Calpains are a family of calcium-dependent cysteine proteases that play a major 
role in the process of axonal and neuronal degradation in ALS and other 
neurodegenerative diseases (Bartus 1997; Ray and Banik 2003).  Although the cause of 
ALS is still unknown, studies have shown that excessive interstitial glutamate, cytosolic 
calcium and oxidative stress upregulate calpain activation.  Activation of intracellular 
calpain leads to proteolysis of calpain-specific substrates such as cytoskeletal proteins, 
microtubule-associated proteins and neurofilament proteins and consequently induces the 
death of neurons (Huang and Wang 2001).  Therapeutic strategies that can inhibit calpain 
activity in the CNS have been shown to be neuroprotective in animal models of many 
neurological disorders.  
Kupina et al. have studied the effect of the calpain inhibitor SJA6017 in the 
treatment of mice suffering from diffuse brain injury.  They measured the 24-hour 
postinjury functional outcome after treating the animals with SJA6017 at different time 
points, and have indicated a potential therapeutic window of 4 hours for diffuse brain 
injury (Kupina, Nath et al. 2001).  Ai et al. also showed that early administration of 
MDL-28170 could protect the brain from focal ischemic brain damage in a rat fluid 
percussion model for up to 3 days (Ai, Liu et al. 2007).  In addition to these promising 
results, calpain inhibitors have also provided several advantages over glutamate receptor 
antagonists and calcium ion channel blockers, such as reduced detrimental side-effects 
outside the central nervous system (Wang, Larner et al. 2006).   
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Among all of the calpain inhibitors, the dipeptide α-ketoamide calpain inhibitors 
have shown the greatest inhibitory potency and specificity for calpains, and thus they 
have the potential to treat ALS (Li, Patil et al. 1993; Harbeson, Abelleira et al. 1994; Li, 
Ortega-Vilain et al. 1996).  However, the solubility of these inhibitors in aqueous solution 
is extremely low and this has limited their clinical applications.  AK295 (Cbz-Leu-
aminobuturate-CONH(CH2)3morpholine), a modified dipeptide α-ketoamide calpain 
inhibitor, was developed to increase the solubility while preserving the effectiveness of 
the drug.  The inhibitory constant  (Ki) of AK295 to calpain I and calpain II are 140 and 
41 nM, respectively (Li, Ortega-Vilain et al. 1996).  This low Ki value indicates that 
AK295 has great potency in the inhibition of calpain.  James et al. showed that AK295 
can inhibit 53-63 % of calpain activity at a 1 µM concentration; however, it almost had 
no inhibitory effects on the degradation of calpain proteolysis substrates such as, 
neurofilament protein (NFP) and myelin basic protein (MBP).  At least a 10 µM 
concentration of AK295 is needed to achieve 50% inhibition of NFP and MBP 
degradation (James, Matzelle et al. 1998).  Bartus et al. also showed that AK295 has a 
dose-dependent neuroprotective effect in a rat focal ischemia model (Bartus, Hayward et 
al. 1994).  All these studies suggested that AK295 bioavailability is an important factor 
for inhibition of calpain related proteolysis.  Although the solubility of AK295 has been 
improved (compared to other dipeptide α-ketoamide calpain inhibitors), its solubility is 
still relatively low (0.13 mg/mL at pH 7.0 and 0.049 mg/mL at pH 8.0) (data from 
SciFinder).  In order to get an optimal pharmacokinetic profile, AK295 needs to be 
dissolved in acidic pH before injection (Saatman, Murai et al. 1996), which might cause 
some unwanted inflammatory effects.  The other drawback of the current AK295 delivery 
9 
 
system is that it requires the animals to receive a continuous intra-arterial infusion of 
AK295 solution up to 54 mL in a 48 hour period.  In the treatment of ALS, a larger 
delivery (volume/dose) may be needed and complications such as, infection, catheter 
obstruction, and discomfort can arise in patients when using this delivery method.   
MDL-28170 is another potent calpain inhibitor used in this thesis.  Unlike 
AK295, MDL-28170 can penetrate the BBB due to its low molecular weight and 
hydrophobicity.   However, like AK295, MDL-28170 needs to be dissolved in acidic 
buffer or organic solvent to get an optimal pharmacokinetic profile, and also has a dose-
dependent neuroprotective effect.  Therefore, the same complications described for 
AK295 might apply to MDL-28170 as well.  Currently, there is no literature describing 
the side effects of MDL-28170 because current applications of MDL-28170 mainly 
focused on the acute diseases such as spinal cord injury (SCI) and acute liver failure 
(ALF).  Galvez et al. (Galvez, Diwan et al. 2007) showed that loss of myocardial calpain 
I activity potentially cause cardiomyocyte degeneration.  Since MDL-28170 is a potent 
calpain I inhibitor, it might increase the risk for heart failure during the treatment of ALS.  
Thus, there is a great need to improve current calpain inhibitor delivery systems. 
CNS barriers for drug delivery  
The goal of my research is to design a drug delivery system which can overcome 
the CNS barriers and enhance the delivery of AK295 in the spinal cord.  An 
understanding of the CNS barriers will be useful for the design of new therapeutic 
strategies. 
The failure of systemically delivered therapeutic agents to effectively treat CNS 
diseases is mainly due to the presence of the highly impermeable blood brain barrier 
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(BBB) (Pardridge 2003) and blood-spinal cord barriers (BSCB).  Both BBB and BSCB, 
which are composed of cerebral capillary endothelial cells and tight junctions, prevent the 
passive uptake of hydrophilic and large molecules into the CNS (Goldstein and Betz 
1986).  Only small molecular weight, uncharged, and lipophilic molecules can passively 
cross this barrier (Habgood, Begley et al. 2000).  Moreover, the endothelial cells of brain 
capillaries have fewer pinocytotic vesicles than those of capillaries elsewhere in the body 
(Pardridge 2002). The transport of molecules, which depends on the cellular transcytosis, 
is therefore severely compromised.  Finally, a number of transport proteins located in the 
luminal membranes of cerebro capillary endothelium are known to be involved in the 
influx and efflux of endogenous and exogenous molecules across the BBB (Kusuhara and 
Sugiyama 2001).  Efflux transport proteins such as P-glycoprotein and multidrug 
resistance associated protein actively remove a wide range of therapeutic agents before 
they cross into the brain parenchyma, and thus effectively restrict drugs from entering the 
CNS (Kusuhara and Sugiyama 2001; Taylor 2002). 
The second barrier for therapeutic drug delivery to the CNS is the blood-
cerebrospinal fluid barrier (BCB).  This barrier is formed by the specialized tight 
junctions of endothelial cells in the choroids plexus.  The BCB closely regulates the 
exchange of molecules between the blood and cerebrospinal fluid (CSF), thus it also 
regulates drug entry into the brain parenchyma.  However, the BCB is not as major of a 
barrier as the BBB.  The surface area of BCB is approximately 1000 fold less than that of 
the BBB (Pardridge 1997). 
These barriers together compose a very delicate control system to maintain 
homeostasis of the CNS.  However, the same control system that protects the brain from 
11 
 
foreign substances also restricts the entry of many potential therapeutic agents. There is a 
great need to find an effective drug delivery system that can overcome these barriers.   
Local drug delivery systems for overcoming CNS barriers 
Drug delivery to the CNS has been particularly inefficient, mainly due to the 
presence of the highly impermeable BBB and BSCB.  The understanding of these barriers 
has been used in the rational design of new therapeutic strategies.   There are a series of 
techniques that have been applied to improve local drug delivery efficacy to CNS.  They 
are discussed below. 
Catheter with pump system  
The simplest and most direct strategy to overcome the barriers to CNS is to 
administer the therapeutic drug directly into the CNS via a catheter system.  Currently, 
implantable catheter pump systems are mainly used for treating brain tumors (Lesniak 
and Brem 2004; Rautioa and Chikhale 2004).  However, researchers have begun to 
explore the feasibility of using this delivery system for ALS therapy.  For example, the 
Alzet Osmotic Minipump system has been used to deliver therapeutic agents (including 
cannabinol, hepactocyte growth factor, amino acids, antibodies and siRNA) for treating 
ALS animals (Nakamura, Kamakura et al. 1997; Weydt, Hong et al. 2005; Ishigaki, Aoki 
et al. 2007; Locatelli, Corti et al. 2007; Urushitani, Ezzi et al. 2007).  This system can 
provide two to four weeks of continuous infusion of drugs in the intrathecal space, 
however, they cannot be refilled, and require surgical removals.  Recently, a more 
advanced implantable infusion pump, the Medtronic SynchorMed system was tested in 
clinical trials for ALS treatment (Nakamura, Kamakura et al. 1997).  This system is able 
to deliver drugs at a constant rate over a prolonged period of time at the intrathecal space 
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through the outlet catheter, and can be refilled by subcutaneous injection.  Despite 
encouraging results, there are still many flaws limiting the success of this type of drug 
delivery system, such as infection, catheter obstruction and discomfort to the patient.  
Local implantation of sustained controlled release polymer 
The objective of implantable polymer-based microparticles for treating CNS 
disease is to provide continuous drug delivery to the CNS using a matrix that also 
protects the drug from degradation. The first generation of controlled release polymer 
system is based on non-biodegradable polymers.  Langer and Folkman first reported the 
sustained and controlled release of macromolecules from an ethylene vinyl acetate 
copolymer (EVAc) (Langer and Folkman 1976).  The encapsulated drug is released by 
diffusion through the micropore of the polymer matrix.  Although EVAcs have found 
applications in glaucoma, diabetes and asthma therapy, it is not specifically FDA 
approved for use in the brain (Lesniak and Brem 2004).  
A major step for developing controlled release polymers in treating CNS diseases 
is the development of biodegradable polymer systems.  Brem and coworkers have studied 
the treatment of recurrent malignant glioma with the anticancer drug carmustine via a 
biodegradable polyanhydride wafer (Brem and Gabikian 2001).  This biodegradable 
polymer, poly[bis(p-carboxyphenoxy) propane-sebacic acid](p(CCP-SA)), releases drug 
by both hydrophobic degradation and drug diffusion.  They demonstrated 
biocompatibility of this polymer system, and sustained release of carmustine in a 
preclinical study (Brem, Mahaley et al. 1991).  After clinical trials, the FDA approved 
carmustine loaded p(CCP-SA) wafer (Gliadel®) for the treatment of malignant glioma.  
Although Gliadel has been used clinically, one of the limitations of this p(CCP-SA) 
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copolymer is that it is designed for delivery of  hydrophobic molecules.  To overcome 
this limitation, the fatty acid dimer-sebacic acid (FAD-SA) copolymer, another 
biodegradable polymer, was developed for delivery of hydrophilic molecules (Domb, 
Maniar et al. 1991).  These two biodegradable polymers share the same mechanism of 
release and the possibility to vary the release kinetics by varying the ratio of the two 
monomers. The sizes of these implantable polymeric devices are several centimeters 
which can provide a large drug depot and sustained release of therapeutic agents for a 
long period of time.  However, the sizes of these polymeric devices are too big for 
intraparenchymal and intraspinal cord implantation and become the major limitations for 
these implantable devices.    
The use of microparticles for delivering therapeutic agents represents a new 
evolving technology for treating CNS disease.  Microparticles are 1 to 1000 µm particles 
that are made of different types of polymers and provide certain benefits as drug delivery 
systems.  For example, microparticles can: 1) effectively protect the encapsulated drugs 
from degradation, 2) provide controlled release of therapeutic agents for long periods of 
time, and 3) can be easily administrated to the targeted area.  With stereotaxic technique, 
the drug-loaded microparticles can be precisely injected to the site of action which makes 
them able to deliver therapeutics to the spinal cord and inoperable brain tumor. 
The general limitation for the above polymeric implant systems is that drug 
release cannot be controlled once the system has been implanted; thus an increased risk 
of local neurotoxicity might occur at higher polymer or therapeutic agent concentrations 
(Rautioa and Chikhale 2004). 
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Microparticles for spinal cord delivery 
Microparticles offer several advantages as drug delivery systems.  With the 
stereotaxic technique, drug loaded microparticles can be precisely injected to the site of 
action within the CNS and provide controlled release properties over a long period of 
time.  However, most of the microparticle studies relevant to treating CNS disorders 
mainly focus on delivery of therapeutic agents to the brain.  Even in spinal cord delivery, 
the microparticles are mainly injected to intrathecal or epidural space and only served as 
a depot for small molecular weight anesthetic drugs which can pass through the BBB 
easily.  Milligan et al. encapsulated pDNA-IL-10 in PLGA microparticles and injected 
these PLGA-pDNA-IL-10 microparticles to the intrathecal space for treating neuropathic 
pain.  They observed that PLGA microparticles can be evenly distributed in the meninges 
but not in the deeper parenchymal spinal cord layers (Milligan, Soderquist et al. 2006).  
For treating ALS disease, the therapeutics need to be able to be delivered into the gray 
matter in the spinal cord.  However, currently no polymeric microparticle formulation has 
been used for intra-spinal cord delivery of therapeutics inside the parenchyma of the 
spinal cord.  This is potentially due to the inflammatory response of current degradable 
polymer systems.  In our preliminary studies, we have shown the PCADK microparticles 
generate minimal inflammatory response in animals.  We therefore anticipate that 
injection of calpain inhibitor-encapsulated PKMs into the spinal cord will cause less 
tissue inflammatory response than other microparticle formulations. 
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Particle size and hydrophobicity of polymer influence the release of hydrophobic 
drug 
Biodegradable nano- and microparticles have been used as controlled drug 
delivery systems to release therapeutic agents at a controlled rate for days, weeks or 
months.  Drug loading and release rates are important parameters in particle-mediated 
drug delivery.  In general, hydrophobic drugs can be encapsulated into particles using an 
oil-in-water emulsion-solvent evaporation method, and usually have a higher 
encapsulation efficiency than hydrophilic drugs.  The release profiles from nano- or 
microparticles are complex due to different interactions between drugs and polymers. The 
main mechanisms of controlled release are driven by the following phenomena: 1) drug 
diffusion to the aqueous solution, 2) drug dissolution from the polymer matrix to the 
solvent, and 3) polymer erosion due to hydrolysis and water penetration (Saltzman 2001).  
The erosion of biodegradable polymers is classified into two types: bulk erosion and 
surface erosion.  The erosion mechanism of a polymer depends on the diffusivity of water 
into the polymer matrix, degradation rate of the polymer due to hydrolysis, and the size 
of the polymer matrix (von Burkersroda, Schedl et al. 2002).  The factors that affect the 
erosion mechanism will influence the release rate of the drug.  Among these factors, most 
of the research showed that two factors, at least, must be taken into account: the 
hydrophobicity of the polymer and the size of the biodegradable nano- or microparticles. 
Thus, a thorough investigation of these two factors affecting drug release profile from 
these polymeric particle devices is critical to the design of optimal delivery systems.    
First, the hydrophobicity of a polymer will influence the water diffusion rate into 
the microparticle and change its drug release profile.  Panyam et al. described that the 
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release rate of dexamethasone, a hydrophobic drug, from PLGA nanoparticles is slower 
when the hydrophobicity of PLGA increased (Panyam, Williams et al. 2004).  In another 
study, Budhian et al. encapsulated haloperidol, a hydrophobic drug, into various PLGA 
nanoparticles which varied in size, polymer hydrophobicity, and particle coatings.  They 
found that increasing the polymer hydrophobicity can extend the period of release 
(Budhian, Siegel et al. 2008).  PLGA 50:50 microparticles completely release haloperidol 
in a 30 day period, while the same size PLA microparticles (more hydrophobic polymer) 
only released 35% of the haloperidol in a 40 day period. 
Second, the size of microsphere is another important factor that affects the release 
rate of hydrophobic drugs. In general, smaller microparticle release drug faster due to an 
increased surface area to volume ratio.  Budhian et al. also showed that increasing the 
particle size can reduce the initial burst effect and extend the period of release within 
nanoparticle formulations (Budhian, Siegel et al. 2008). Their data showed that 50% of 
the haloperidol was released in the first day from 220 nm PLGA nanoparticle, while only 
10 % was released from 1300 nm PLGA microparticles in the same period.  This is 
because the larger size increases the length of the diffusion pathway for the drug and 
prevents the initial burst. 
  The particle size also affects the erosion mechanism of the polymer.  According 
to the research done by von Burkersroda et al., polyketals will undergo bulk erosion 
when the polymer devices are smaller than 400 µm (von Burkersroda, Schedl et al. 2002).   
Polyketal-based delivery systems have potential for treating CNS disease 
Polyketals are a new family of biodegradable polymers designed for drug delivery 
(Heffernan and Murthy 2005; Lee, Yang et al. 2007; Yang, Bhide et al. 2008).  
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Microparticles formulated from polyketals degrade into neutral compounds and should 
therefore prevent the inflammatory problems associated with polyester-based and poly-
anhydride-based delivery devices.  In the last decade, researchers have found increasing 
evidence demonstrating that inflammation and inflammatory mediators contribute to 
acute, chronic CNS degenerative diseases (Lucas, Rothwell et al. 2006).  For example, 
Tehranian et al. found that inflammatory mediators such as tumor necrosis factor-α 
(TNF-α), IL-1, and IL-6 were upregulated in closed head injury model (Tehranian, 
Andell-Jonsson et al. 2002).  Yoshihara et al. found that the levels of TNF-α are elevated 
in ALS SOD1 mutant mice, suggesting that inflammation contributes to ALS (Yoshihara, 
Ishigaki et al. 2002).  Therefore, an ideal implantable polymer drug delivery system 
should produce minimal inflammation, which makes polyketal microparticle a good 
candidate for CNS delivery. 
Currently, a number of polyketals have been synthesized for drug delivery 
applications, poly(1,4-phenyleneacetone dimethylene ketal) (PPADK), 
poly(cyclohexane-1,4-diyl acetone dimethylene ketal) (PCADK), and copolymers of 
PCADK (Heffernan and Murthy 2005; Lee, Yang et al. 2007; Yang, Bhide et al. 2008).  
PPADK has rapid hydrolysis kinetics, but degrades into benzene dimethanol, a 
compound with potential toxicity, due to its aromatic ring (Heffernan and Murthy 2005).  
PCADK and PCADK-copolymers, in contrast, degrade into acetone and 1,4-
cyclohexanedimethanol, both of which have excellent biocompatibility.  PCADK has a 
hydrolysis half-life of 24 days at pH 4.5 (Lee, Yang et al. 2007), thus PCADK 
microparticles can slowly release drugs for a long period of time which makes PCADK 
microparticles desirable delivery devices for chronic neural degenerative diseases such as 
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Parkinson’s disease, Alzheimer’s diseases, and ALS.  Copolymers of PCADK have been 
developed as drug delivery vehicles for the treatment of acute liver failure because of 
their neutral degradation products and tunable hydrolysis kinetics (Yang, Bhide et al. 
2008).  In particular, one PCADK copolymer, PK3, has a hydrolysis half-life of 2 days at 
pH 4.5 and several weeks at pH 7.4.  Microparticles formulated from PK3, encapsulated 
with the kinase inhibitor imatinib, demonstrated improved efficacy in the treatment of 
acute liver failure caused by the immunotoxin Concavalin A, in vivo.  Therefore, 
microparticles formulated from PK3 should be suitable for treating acute CNS injuries, 
such as traumatic brain injury (TBI), because they hydrolyze and release therapeutics 
rapidly in the acidic phagolysosomes of microglia and astrocytes, and also release 
therapeutics in the neutral extracellular environment in a sustained manner.  
Polyketal-based delivery systems have shown to have high encapsulation 
efficiency in the loading of small hydrophobic drugs; however, a major limitation of 
current polyketal-based delivery systems is low encapsulation efficiency of large proteins 
or other hydrophilic compounds.  This is possibly due to the low molecular weight of 
currently used polyketals.  For example, the typical Mn of a polyketal used in previous 
study ranges between 2,000 and 3,000 Daltons, whereas PLGA with a Mn of 10,000 
Dalton or larger is used to encapsulate proteins for drug delivery applications.  The 
encapsulation efficiency of lysozyme in PLGA microparticles is typically higher than 39 
% (Taluja, Youn et al. 2007).  On the other hand, polyketals can only achieve less than 16 
% encapsulation efficiency using double emulsion procedures.  In this research, we 
planned to improve the loading efficiency of PKMs by increasing the molecular weight 




DEVELOP HIGH MOLECULAR WEIGHT POLYKETALS THAT 
PROVIDE SUSTAINED RELEASE PROPERTIES FOR 
HYDROPHOBIC MOLECULES 
2.1 Introduction 
In this chapter, we discuss Specific Aim 1 which is to develop a hydrophobic dye 
encapsulated polyketal microparticle which has an in vitro release half-life of one month 
at pH 7.4. To reach this goal, we first synthesized a high molecular weight polyketal and 
used it to encapsulate hydrophobic dyes.  The release kinetics of the dye from the 
microparticles were optimized by altering the particle size.  In this section, we also 
describe the other applications of high molecular weight polyketals.  Although the high 
molecular weight polyketals are originally developed for preparation of calpain inhibitor-
loaded microparticles, we also found several new applications of high molecular weight 
polyketals such as 1) improving the encapsulation of AOPHA-Me, an anti-inflammatory 
drug for arthritis, and 2) fabricating siRNA loaded nanoparticles that can be delivered to 
the non-phagocytic cells, such as endothelium cells.  We also discuss these new 
applications in this chapter. 
Synthetic biodegradable polymers such as polyesters, polyorthoesters and 
polyanhydrides have been extensively investigated for controlled drug delivery 
applications.  However, these polymers generate acidic degradation products which are 
not suitable for treating inflammatory diseases (Fu, Pack et al. 2000; Tamber, Johansen et 
al. 2005; Sugiyama, Yamashita et al. 2007).  Therefore, there is a great need for 
developing new biodegradable polymers which have tunable hydrolysis profiles and most 
importantly, can degrade into neutral compounds.  Polyketals are novel biodegradable 
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polymers which have ketal linkages in their backbone that can be rapidly hydrolyzed in 
an acid environment (Heffernan and Murthy 2005; Lee, Yang et al. 2007; Yang, Bhide et 
al. 2008).  The hydrolysis rates of polyketals can be tailored for a specific application by 
varying the ratios of hydrophilic copolymers incorporated in the polyketal formulations 
(Yang, Bhide et al. 2008). Unlike other polyester-based materials, polyketals do not 
generate inflammatory acidic degradation products, but rather degrade into the neutral 
products acetone and diols, thus they should have great potential for treating 
inflammatory diseases (Lee, Yang et al. 2007; Sy, Seshadri et al. 2008; Yang, Bhide et al. 
2008).   
Currently, a number of polyketals have been synthesized, however, only 
poly(cyclohexane-1,4-diyl acetone dimethylene ketal) (PCADK), and copolymers of 
PCADK are suitable for drug delivery due to their tunable hydrolysis property and 
excellent biocompatibility (Lee, Yang et al. 2007; Sy, Seshadri et al. 2008; Yang, Bhide 
et al. 2008). In our laboratory, we have delivered several therapeutic agents to treat 
inflammatory diseases using the microparticles formulated from PCADK and its 
copolymers.  For example, Sy et al. showed that delivery of p38 inhibitor-loaded PCADK 
microparticles to the damaged myocardium can improve the treatment of cardiac 
dysfunction (Sy, Seshadri et al. 2008).  Microparticles formulated from PK3, 
encapsulated with the kinase inhibitor imatinib, demonstrated improved efficacy in the 
treatment of acute liver failure caused by the immunotoxin Concavalin A, in vivo (Yang, 
Bhide et al. 2008). 
Although polyketal-based delivery systems have shown great potential for 
treating inflammatory diseases, the loading efficiency of therapeutic agents is lower than 
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the other commercially available biodegradable polymer such as PLGA (Giovagnoli, 
Blasi et al. 2004; Lee, Yang et al. 2007).  To reach a therapeutic effect, we have to 
deliver drug loaded polyketal microparticles at higher dosage which limits its clinical 
application.  This is possibly due to the low molecular weight of these current polyketals. 
The low molecular weight issue also hindered the development of polyketal 
polymers with fast hydrolysis kinetics. In our previous report, polyketal copolymers with 
higher incorporation of 1,5-pentanediol were also generated; however those copolymers 
have a low molecular weight and were viscous liquids (Yang, Bhide et al. 2008), which 
are not suitable for formulation into microparticles for drug delivery. 
Given these limitations with current polyketal polymers, a new synthetic 
methodology which can increase the molecular weight of polyketals and expand their 
applications ia needed.  The polyketals are synthesized via step-growth polymerization, 
we therefore speculate that their low molecular weight is due to an imbalance of the 
reactants during the polymerization process (Stille 1981).  Although the diols and ketal 
are initially mixed at a 1 to 1 ratio (mol/mol), there is a significant loss of the 2,2-
dimethoxypropane (DMP) during the polymerization, therefore altering the stoichiometry 
balance of the reactants.  This is because the reaction occurs at 100 oC to remove the 
byproduct methanol, but also removes the DMP which has a boiling point of 83 oC, 














Scheme 2.1 A novel methodology to synthesize high molecular weight polyketals using 
DEP formulation. 
 
In this section, we used an alternative ketal, 2,2-diethoxypropane (DEP), which 
has a boiling point of 117 oC, which is above the reaction temperature (100 oC), for this 
acetal-exchange reaction to alleviate the removal of the reactants.  However, in our first 
few experiments, we could only slightly increase the molecular weight of PK3 by using 
the DEP method.  Thus, we speculate that there was still some DEP being evaporated 
with benzene and ethanol.  Inspired by Tobita and Ohtan’s intermediate monomer feed 
method (Tobita and Ohtani 1991), we added additional ketal (DEP or DMP) two hours 
after the reaction starts.  The primary results showed a dramatic increase in molecular 
weight by adding additional DMP but not DEP.  The optimal result was obtained by 
starting the reaction with DEP and diol at a 1 to 1 ratio (mol/mol) and adding additional 
DMP at a later time point to compensate for the loss of DEP during the reaction (Scheme 
1).  The properties of resulting polyketals were characterized by GPC, NMR, and DSC.  
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Figure 2.1 Comparison between calpain inhibitors and hydrophobic fluorescent dyes  
The goal of my research is to formulate a polyketal microparticle delivery system 
which can release calpain inhibitors to the spinal cord in a sustained manner.  To reach 
this goal, three different hydrophobic dyes (Nile Red, DiI and coumarin-6) were chosen 
as model compounds for the calpain inhibitors because they have similar hydrophobic 
profiles as calpain inhibitors and should have similar release kinetics (Figure 2.1). The 
polyketal microparticle formulations were optimized by comparing the release kinetics of 
the dye from various microparticle formulations.  The encapsulation efficiency of DiI-
PKMs was analyzed by fluorescence spectrometry.  The physical properties of the 
resulting dye encapsulated microparticles were also investigated. 
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2.2 Experimental Methods 
Material  
2,2-diethoxypropane (DEP, acetone diethylacetal) was purchased from TCI 
(Tokyo, Japan).  Double stranded fl-TNF-α siRNA (sense strand: 5’–GAC AAC CAA 
CUA GUG GUG CUU–3’) was synthesized by Dharmacon (Lafayette, CO).  1,2-
Dioleoyl-3-Trimethylammonium-Propane (Chloride Salt) (DOTAP) was purchased from 
Avanti Polar Lipids, Inc. (Alabaster, AL). All other chemicals were purchased from 
Sigma-Aldrich (St. Louis, MO) and used as received unless otherwise specified. 
Benzene, 2,2-dimethoxypropane and DEP were purified by distillation. AOPHA-Me was 
a gift from Dr. May. 
Develop a new method for the synthesis of high molecular weight polyketal 
Synthesis of PCADK copolymers   
Briefly, polyketal copolymer PK8 was synthesized in a 100 mL two-necked flask, 
connected to a short-path distilling head. The diols, 1,4-cyclohexanedimethanol (CDM) 
(5 g, 34.86 mmol) and 1,5-pentanediol (0.908 mL, 8.72 mmol) were dissolved in 15 mL 
of distilled benzene and kept at various temperatures (90, 95, 100 and 110 °C).  Re-
crystallized p-toluenesulfonic acid (PTSA) was dissolved in ethyl acetate (1 mg/mL) 
prior to the reaction, and various amounts of the PTSA ethyl acetate solution were added 
to the reactions to study the effect of PTSA on the molecular weight of PK8.  The added 
ethyl acetate was distilled off, and distilled 2,2-diethoxypropane (equal molar ratio to the 
two diols combined) was added to initiate the reaction. The reactions were kept at various 
temperatures (90, 95, 100 and 100 °C) to optimize the molecular weight of PK8.  
Additional doses of ketals (1 mL) and benzene (4 mL) were subsequently added to the 
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reaction 2 hours later, via a pressure equalizing funnel, to compensate for the 2,2-
dimethoxypropane and benzene that had been distilled off.  Another two doses of 5 mL 
benzene were added to the reaction at hours 6 and 24 to decrease the viscosity of the 
reaction mixture.  After 48 hours, the reaction was quenched by adding triethylamine 
(120 μL).  PK 9 and PK10 were synthesized using the optimized reaction conditions from 
PK8 except using higher ratios of 1,5-pentanediol in the starting materials.  The starting 
1,5-pentanediol/CDM ratio was 30/70 for PK9 and was 40/60 for PK10. The resulting 
copolymers were analyzed by 1H-NMR and GPC. 
 
Synthesis of PCADKe 
PCADKe was synthesized by using the DEP/DMP method as described above 
except that an extra toluene or benzene was added to the reaction to decrease the 
viscosity of the reaction solution. Briefly, the diol, 1,4-cyclohexanedimethanol, were 
dissolved in distilled benzene and kept at 95 °C.  Known amounts of re-crystallized p-
toluenesulfonic acid (PTSA) or pyridinum p-toluenesulfonate (PPTSA) (Acros organic, 
New Jersey, USA), dissolved in ethyl acetate, were added to the reaction.  Distilled 2,2-
diethoxypropane (equal molar to the CDM) was then added to initiate the reaction.  
Additional doses of 2,2-dimethoxypropane (1 mL) and benzene (4 mL)  were 
subsequently added to the reaction 2 hours later, via a metering funnel, to compensate for 
2,2-dimethoxypropane and benzene that had been distilled off.  The viscosity of the 
reaction increases with increasing molecular weight and decrease the mixing efficiency, 
which lower the reaction yield. Two methods were used to decrease the viscosity of the 
reaction: 1. An extra volume of toluene was added 6 hours later after the start of the 
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reaction. 2. Small amount of benzene were constantly added by pressure equalizing 
funnel (1 mL/h). After 48 hours, the reactions were stopped by adding triethylamine (120 
μL).  Different reaction times were used to optimize the molecular weight of PCADKe. 
PCADKe was isolated by precipitation into cold hexanes and analyzed by 1H-NMR and 
GPC. 1H NMR data of PCADK (400 MHz, CDCl3, δ): 3.26 – 3.18 (m, 4H, C4H8CH2O), 
1.83 – 0.93 (m, 8H, CH2 from cyclohexane, axial and equatorial), 1.32 (s, 6H, 
CH2OC(CH3)2 OCH2). 
 
Nuclear magnetic resonance (NMR) 
The compositions of the polyketal copolymers were analyzed by 1H NMR.  1H 
NMR spectra were obtained from a Varian Mercury VX 400 MHz NMR spectrometer 
(Palo Alto, CA) using CDCl3 as the solvent.  1H NMR data of PK8 (400 MHz, CDCl3, δ): 
3.4 – 3.18 (m, 4H, CH2), 1.66 (s, 2H, CH), 1.85 – 0.93 (m, 8H, CH2), and 1.32 (s, 6H, 
CH3). 1H NMR data of PK 9 (400 MHz, CDCl3, δ): 3.4 – 3.18 (m, 4H, CH2), 1.66 (s, 2H, 
CH), 1.85 – 0.93 (m, 8H, CH2), and 1.32 (s, 6H, CH3). 1H NMR data of PK10 (400 MHz, 
CDCl3, δ): 3.4 – 3.18 (m, 4H, CH2), 1.66 (s, 2H, CH), 1.85 – 0.93 (m, 8H, CH2), and 1.32 
(s, 6H, CH3). 
 
Gel permeation chromatography (GPC) 
The molecular weights of the polyketal copolymers were determined by gel 
permeation chromatography (GPC) using a Shimadzu system (Kyoto, Japan) equipped 
with a UV detector.  Tetrahydrofuran (THF) was used as the mobile phase at a flow rate 
of 1 mL/min.  Polystyrene standards (Peak Mw = 1,060, 2,970, 10,680 and 19,760) from 
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Polymer Laboratories (Amherst, MA) were used to establish a molecular weight 
calibration curve. 
 
Characterization and performance of high molecular weight polyketals 
Hydrolysis of PK3, PK8 and PK10 at pH5 and pH7.4 
The hydrolysis of polyketal polymers was measured according to the procedures 
of Lee et al (Lee, Yang et al. 2007). The hydrolysis of PK3, PK8 and PK10 was measured 
by 1H NMR in buffered water at the pH values of 5.0 (100 mM AcOH) and 7.4 (100 mM 
NaH2PO4) at 37°C.  For each time point and pH, three samples were analyzed.  For each 
sample, 15 mg of polymer (ground powder) were suspended in 1 mL of aqueous solution, 
at the appropriate pH, and shaken at 120 rpm and 37°C, using a Labline incubated shaker 
(Barnstead International, Dubuque, Iowa).  At specific time points, the polymer samples 
were extracted with 1 mL of CDCl3, and analyzed by 1H NMR, to determine the percent 
of ketal linkages that were hydrolyzed. 
 
Preparation and characterization of AOPHA-ME PCADK microparticle 
The anti-inflammatory prodrug 5-(Acetylamino)-4-oxo-6-phenyl-2-hexenoic Acid 
Methyl Ester (AOPHA-Me) was encapsulated into microparticles using a single oil-in-
water emulsion, solvent evaporation method.  Briefly, 50 mg of AOPHA-Me and 450 mg 
of PCADKe were dissolved in 2 mL of dichloromethane.  This solution was combined 
with 16 mL of 5 % poly(vinyl alcohol) (PVA) phosphate buffer solution (pH 7.4) and the 
mixture was homogenized at 21,500 rpm for 2 minutes.   The resulting oil-in-water 
emulsion was added to 20 mL of 1 % PVA phosphate buffer solution (pH 7.4) and stirred 
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for 4 hours, evaporating the dichloromethane and forming particles. The resulting 
particles were washed twice in deionized water (with centrifugation at 10,000 rpm) to 
remove the PVA, and lyophilized, yielding 400 mg of particles.  SEM images of the 
AOPHA-Me-encapsulated PCADKe microparticles (AOPHA-Me-PKMs) and blank 
PCADKe microparticles showed their size is between 1-2 µm.   
The encapsulation efficiency and loading of AOPHA-Me PKMs was analyzed by 
reverse phase HPLC.  Briefly, 3-6 mg of AOPHA-Me PKMs were dissolved in 1 mL of 
40 % acetonitrile, 0.1 % TFA solution.  The resulting solution was then injected into a 
Shimadzu HPLC with a Prevail C18 Column using a 40 % acetonitrile, 0.1% TFA mobile 
phase at 1.0 mL/min with a PDA detector set from 190-300 nm.  A standard curve of 
AOPHA-Me was generated from 0.053 mg/mL to 0.00053 mg/mL to fit a least square 
linear regression.  Blank PKMs were also analyzed as control. 
 
Formulation of PCADKe nanoparticles 
Briefly, 40 mg of PCADK (Mw=2,849 Da) or PCADKe (Mw=12,364 Da) were 
dissolved in 1mL dichloromethane containing DOTAP (75 nmole).  The solutions were 
combined with 8 mL of 1 % poly(vinyl alcohol)(PVA) phosphate buffer solution (pH 7.4) 
and the mixture was sonicated for 2 minute at 20 W (Branson Sonifier 250) to form a fine 
oil/water emulsion.   The resulting oil-in-water emulsion were added to 10 mL of 0.4 % 
PVA Phosphate buffer solution (pH 7.4) and were stirred for 4 hours, evaporating the 
dichloromethane to form particles. The resulting particles were washed three times in 




Scanning Electron Microscopy (SEM) 
SEM images were taken to analyze the morphology of the polyketal 
microparticles.  Briefly, SEM samples were prepared by attaching lyophilized particles 
onto 12.7 mm diameter aluminum sample mounting stubs (Electron Microscopy 
Sciences, Hatifield, PA), using conductive double sided carbon discs (SPI Supplies, West 
Chester, PA).  The samples were coated with a gold sputter coater (International 
Scientific Instruments, Prahran, Australia) for 1 minute under an argon atmosphere.  The 
SEM samples were subsequently analyzed using either a HITACHI S-800 or LEO-1530 
scanning electron microscope (Tokyo, Japan).   
 
Dynamic Light Scattering 
Particle sizes and distributions were determined by dynamic light scattering 
(DLS) using a 90plus particle size analyzer (Brookhaven, Holtsville, NY)  
 
Thermal analysis of polyketal polymers 
Thermal analyses of the polyketal polymers was carried out on a differential 
scanning calorimeter (DSC, Thermal Analysis Instruments, Q100) at a temperature ramp 
from 0 to 300 oC at 10 oC/min with a nitrogen purge rate of 10 mL/min. Glass transition 
temperature (Tg) was taken as the inflexion of the DSC curve and melting temperature 
(Tm) was taken as the peak temperature of the endothermic peak using TA Instruments 





In vitro uptake of fl-siRNA encapsulated nanoparticles by HUVEC cells 
Ion-paring of fl-siRNA 
Fl-TNF-α siRNA (75 nmole) dissolved in 0.5 mL of RNase-free water was added 
to an equal volume (0.5 mL) of methylene chloride containing an equal molar cation of 
DOTAP (3.15 μmole).  Methanol (1.05 mL) was then added to two phase solution to 
make a single phase solution. The monophase was gently mixed and allowed to stand for 
15 min.  The mixture was separated by adding 0.5 mL of each of the aqueous phase 
(RNase free water) and organic phase (methylene chloride).  The resulting solutions were 
gently mixed for 1 min and centrifuged at 600 x g for 5 min.  The organic bottom phase 
(1 mL) was rapidly pippeted out and used for further experiments. 
 
Formulation of fl-siRNA PCADKe nanoparticles  
Briefly, 40 mg of PCADKe (Mw=12,234) wa dissolved in 1mL of 
dichloromethane containing DOTAP fl-siRNA (75 nmole).  The solutions were combined 
with 8 mL of 1% poly (vinyl alcohol) (PVA) phosphate buffer solution (pH 7.4) and the 
mixture was sonicated for 1 minute at 20 W (Branson Sonifier 250) to form a fine 
oil/water emulsion.  The resulting oil-in-water emulsion was added to 10 mL of a 0.4 % 
PVA phosphate buffer solution (pH 7.4) and was stirred for 4 hours, evaporating the 
dichloromethane to form particles. The resulting particles were washed three times in 
deionized water (with centrifugation at 15,000 rpm, 20 minutes) to remove PVA and 





In vitro uptake of fl-siRNA PKNs by HUVEC cells 
Human umbilical vein endothelial cells (HUVECs; Genlantis), (a gift from Dr. 
Gang Bao), were cultured in endothelial cell growth medium (Genlantis) 
supplemented with 20 % fetal bovine serum, 13.3 U/ml heparin, 40 µg/ml endothelial 
mitrogen (Biomedical Technologies), 1 % L-glutamine, and penicillin-streptomycin.  For 
flow cytometry, HUVECs (1x106 cells/well, 12 well plate) were incubated with fl-siRNA 
nanoparticles for 4 h.  The cells were washed 3 times and then incubated with fresh 
medium for 24 h.  Cells were washed 3 times with ice cold PBS and scraped into tubes 
for the flow cytometry.   Fluorescent cell population was measured by a flow cytometer 
(BD LSR flow cytometer, BD Bioscience) (San Jose, CA) using a laser for fluorescein 
(λex/λem = 494/510 nm).  
 
In vitro release of hydrophobic dyes from PCADKe microparticles 
Preparation of dye encapsulated PCADKe microparticles 
The size of the microspheres is another important factor that affects the release 
rate of hydrophobic drugs (Budhian, Siegel et al. 2008).   The speed of homogenization 
during an oil/water single-emulsion process can affect the size of microparticles (Zhao, 
Gagnon et al. 2007).  Thus, we used various homogenization speeds to prepare dye 
encapsulated PCADK microparticles (dye-PKMs) to determine the relation between 
particle size and speed of homogenization.  Three different hydrophobic dyes (Nile Red, 
DiI and coumarin-6) were chosen as model compounds for the calpain inhibitors because 
they have similar hydrophobic profiles as the calpain inhibitors and should have similar 
encapsulation efficiencies.   Each dye was encapsulated by an oil/water single-emulsion  
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Briefly, 0.5 mg of dye (Nile Red, DiI or coumarin-6) and 50 mg PCADK were dissolved 
in 500 µL of a single-phase solvent (1:3 N,N-dimethylformanide: dichloromethane). This 
solution was combined with 5 mL of 5 % poly(vinyl alcohol)(PVA) Tris buffer solution 
(pH 9.0) and the mixture was homogenized at three different speeds (24,000, 17,500 and 
9,800 rpm) for 1 minute to generate different particle sizes of dye-PKMs.  The resulting 
oil-in-water emulsion was then added to 20 mL of 1 % PVA Tris buffer solution (pH 9.0) 
and stirred for 4 hours, evaporating the dichloromethane to form particles. The resulting 
particles were washed three times in deionized water (with centrifugation at 10,000 rpm) 
to remove dimethylformanide and PVA, and lyophilized. The sizes and morphologies of 
dye-PKMs (Nile Red-PKMs, DiI-PKMs and comarin-PKMs) were visualized on a 
Hitachi S-800 SEM.   
 
In vitro release of hydrophobic dyes from PCADK microparticles 
The release kinetics of the PKMs was optimized by using a fluorescent dye, 1,1′-
Dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate (DiI), as a model 
compound for AK295.  Dil was chosen as a model compound because it has a similar 
hydrophobicity profile as AK295 and should therefore have similar release kinetics. The 
release of Dil was measured by fluorescence spectrometry.  PKMs with various sizes 
(1.96± 0.64 μm, 2.90± 1.17 μm and 5.49 ± 3.21 μm) were prepared and their release rates 
were characterized and optimized.  
Briefly, a 10 mg sample of DiI PKMs (containing 75 µg of DiI dye) were added 
to a 2 mL microcentrifuge tube and suspended with 1200 µL of PBS (pH 7.4).  The 
microcentrifuge tubes were shaken at 120 rpm, 37oC.  At different time intervals (1, 3, 6, 
33 
 
12, 24 hours, 3, 7, 14, 28, and 60 days), the particle suspension were centrifuged at 
10,000 rpm for 15 min.  An 1100 µL volume of the supernatant was pipetted out and 
transferred to another micricentrifuge tube.  This supernatant was then recentrifuged at 
10,000 rpm for 15 min to minimize the particles present in the solution.  A 1000 µL 
volume of the supernatant was pipetted out and the same volume of fresh buffer was 
added to the tube.   The resulting supernatants were then mixed with equal volume of 0.2 
% SDS solution to maximize fluorescent signal.  The concentrations of DiI released into 
the supernatant were measured by Fluorescence spectrometry (λex= 550 nm, λem= 565 
nm).  At the last time point (60 days) the remaining particles were hydrolyzed and the 
amount of unreleased DiI dye the particles were measured and used to calculate the 






Synthesis of polyketals using DEP/DMP method 
Optimization of PK8 copolymer 
PK8 was synthesized on a multi-gram scale with a yield of 36 %.  By different 
ketal ratios, various molecular weights of PK8 were synthesized, the result was shown in 
Table 2.1. The reaction was conducted at the various reaction temperatures (90, 95, 100, 
and 105 oC), to optimize reaction temperature, and the results was shown in Figure 2.2. 
An 1H-NMR spectrum and GPC spectrum are shown in Figure 2.3, confirming its 
chemical structure and molecular weight. 
The highest molecular weight of PK8 (Mw/Mn = 11,171/6,500) was obtained at 
the following condition: Initiated the reaction with diols (80 % CDM/ 20 % 1, 5-
pentanediol) and equal molar of distilled DEP and three dosage of DMP (1mL) at present 
of PTSA (1.5 mg) at 95 oC for 48 hours.  This optimized condition was used to synthesize 
the other polyketals. 
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Table 2.1 Optimization of PK8.   












0 3.5 2,907/1,243 NA 
0 2.0 3,827/1,506 NA 
0 1.5 5,239/2,708 6,037/3,227 
1 mL of DEP 1.5 4,865/2,577 NA 
3 mL of DEP 1.5 3,606/1,208 NA 
1 mL of DMP 1.5 8,035/4,349 9,081/4,619 
2 mL of DMP 1.5 8,408/4,349 9,803/5,540 
3 mL of DMP 1.5 8,241/4,961 11,171/6,500 
5 mL of DMP 1.5 6,977/3,204 82,54/4,805 
All polymerizations were conducted at 95 oC for 48 hours and the molecular weight of 




































Figure 2.3 (A) 1H-NMR and (B) GPC spectra of PK8. 
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By using this DEP/DMP mixture technique, we improved the molecular weights 
of polyketals and have also developed new polyketal copolymers which can incorporate 
higher 1,5-pentanediol ratios within the copolymers. The compositions and molecular 
weights of the polyketal copolymers synthesized from DEP/DMP mixtures are 
summarized in Table 2-2.  The PK10 had the highest 1,5-pentanediol incorporated (30 %) 
however, the molecular weight was lower than the other copolymers.  Similarly, PK9, 
incorporated 18.7 mole % of 1,5-pentanediol, had a medium molecular weight (Mw/Mn= 
7,494/4,511), which is higher than PK10 but lower than PK8. The 1H-NMR spectrum and 
GPC spectrum of PK9 and PK10 are shown in Figure 2.4 and Figure 2.5 respectively, 
confirming their chemical structure and molecular weight. 
 
Table 2.2 Compositions and molecular weights of polyketal copolymers and PCADK 
synthesized from DEP/DMP mixtures 




PK8 80/20 82.99/17.01 12,136/6,338 30 % 
PK9 70/30 81.30/18.70 7,494/4,511 20 % 
PK10 60/40 69.45/30.55 6,408/2,974 10 % 





















Figure 2.5 (A) 1H-NMR and (B) GPC spectra of PK10 
 
We also used the same technique and condition to synthesize PCADKe, however, 
the reaction became very viscous after we added the additional DMP, consequently 
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forming a solid bulk PCADK and halted the polymerization.  The resulting PCADKi 
(insoluble PCADK) polymer had very low solubility in both THF and DCM at room 
temperature. To avoid damage of the GPC column, we centrifuged and filtered the 
PCADKi-THF solution to remove the insoluble part of PCADKi, and only measured the 
soluble part of PCADKi.  The results showed that the PCADKi’s molecular weight was 
only slightly higher than the original PCADK synthetic method. 
 
Optimization of PCADKe 
PCADKe was synthesized at a multi-gram scale with yield of 53 % by using a 
modified DEP/DMP method. To decrease the viscosity of the reaction and enhance the 
mixing efficiency, we either added an extra volume of toluene or continuously added 
small amount of benzene to the reaction. The optimized results were shown in Table 2.3 





Additional Solvent Catalyst Mw/Mn 
1*  
20 mL of 
Benzene 
0 PTSA 4764/3103* 
2 3 mL of toluene PTSA 6833/3583 
3 1mL of benzene per 
hour, for 48 hour 
PTSA 10191/4968 
4 PPTSA 7205/3841 
All  polymerizations were conducted at 95 oC for 48 hours and the molecular weight of 
PCADKe were measured by GPC.  
* the reaction was stopped at 24 hours due to formation of insoluble PCADKi. 
 
The results showed that only continuously added small amount of benzene can 
generate high molecular weight PCADKe.  Although the toluene is not evaporated under 
these conditions, an extra volume of toluene also diluted the concentration of the 
reactants and therefore the molecular weight of PCADKe only increases slightly.  Thus, 
the modified DEP/DMP methods described below were conducted by continuously 





































































Figure 2.6 Optimization of reaction temperature for PCADKe using (A) PTSA, (B) 
PPTSA as catalyst 
 
To optimize the reaction temperature, the reactions were conducted at the various 
reaction time (6, 24, 48, and 72 hour), and the results were shown in Figure 2.6 (A). We 
also tried to use different catalyst pyridinum p-toluenesulfonate (PPTSA) to avoid the 
degradation due to acid hydrolysis. However, PTTSA is also less efficient than PTSA, 
thus the molecular weight of PCADKe generated by PTTSA is lower than PCADKe 











Figure 2.7 (A) 1H-NMR and (B) GPC spectra of PCADKe 
The 1H-NMR spectrum and GPC spectrum of PCADKe is shown in Figure 2.7, 
confirming its chemical structure and molecular weight. 
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Characterization and performance of high molecular weight polyketals 
Hydrolysis of PK3, PK8 and PK10 at pH5 and pH7.4 
The hydrolysis of PK3, PK8 and PK10 were measured by 1H NMR in buffered 
water at the pH values of 5.0 and 7.4 at 37°C to determine their behavior in the acidic 
environment of phagolysomes and in the blood.  Figure 2.6 demonstrates that all 
polyketal copolymers undergo acid hydrolysis.  The hydrolysis half-lives of PK 3, PK8 





























































Figure 2.8 Hydrolysis of PK3, PK8 and PK10 at (A) pH 5.0 and (B) pH 7.4 environment 
Enhanced loading of anti-inflammatory drug AOPHA-Me with high molecular weight 
PCADKe 
Although the high molecular weight polyketals are originally developed for 
preparation of calpain inhibitor-loaded microparticles, we also explore their potential 
application in delivery the other therapeutic agents. An anti-inflammatory drug AOPHA-
Me was encapsulated into two different molecular weights of PCADK microparticles, 
and compared their encapsulation efficiency.  The encapsulation efficiency of AOPHA-
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Me into PKMs was calculated to be 3 ± 1 % (n=4) and the loading of AOPHA-Me into 
PKMs was 3 ± 1 μg AOPHA-Me per 1 mg of particles.  By using lower Mw PCADK, the 
loading of AOPHA-Me into PKMs was 0.7 ± 0.6 μg AOPHA-Me per 1 mg of particles 
(n=7).  The morphology of AOPHA-Me PKMs prepared from two different molecular 
weight PCADKe were shown in Figure 2.9 
             
A B 
Figure 2.9 SEM images of AOPHA-Me PKMs prepared from (A) high molecular weight 
PCADK (Mw=9,623), (B) medium molecular weight PCADK (Mw=6,317). 
 
Nanoparticles formulated from high molecular weight PCADKe are stable 
Formulation of PCADKe nanoparticles 
We demonstrated that both high and low Mw PCADK can form nanoparticles 
after sonication, however only nanoparticles made from high Mw PCADK remain intact 
during centrifugation step (Figure 2.10 (A)) while the nanoparticles made from low 
molecular weight collapsed in the same condition (Figure 2.10 (B)). The size of the high 
molecular weight PKMs is 377.9 ±19.5 nm (by DLS) and the size of the low molecular 
weight PKMs is not available due to deformation.  We also tried to prepare nanoparticles 
with PK8, which have similar molecular weight as high Mw PCADK, however, the PK8 
nanoparticles also collapsed during centrifugation as low Mw PCADK nanoparticles 
(data not shown). 
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A B 
Figure 2.10 SEM images of PCADKe nanoparticles prepared from (A) High molecular 
weight PCADKe (Mw/Mn = 12,234/6,623) and (B) low molecular weight PCADK 
(Mw/Mn = 2,849/1,981) 
 
Thermal analysis of polyketal polymers 
Thermal analyses of the polyketal polymers were carried out on a differential 
scanning calorimeter (DSC) and results were shown in Figure 2.11 and Table 2.4.  In 
general, the high molecular weight PCADKe has higher melting temperature (Tm) and 
glass transition temperature (Tg) than the low molecular weight PCADK and, the 
PCADK has higher Tm than PCADK copolymers. 
 
Figure 2.11 DSC of polyketals. (A) High molecular weight  PCADK, (B) Medium 





Table 2.4 The DSC results of polyketal polymers. 
 












High Mw PCADKe 100 0 12,234/6,623 288 133 
Medium Mw PCADK  100 0 5,407/3,265 257 115 
Low Mw PCADK 100 0 2,849/1,981 241 106 
PK3 87 13 4,503/2,593 248 105 
PK8 83 17 11,548/5,651 252 101 
PK10 70 30 6,448/3,609 98 48 
 
Enhance the in vitro uptake of fl-siRNA PKNs in HUVEC cells 
Fluorescein-labeled siRNA (fl-siRNA) was encapsulated within the PCADKe 
nanoparticles with an encapsulation efficiency of 35.6 %.  The SEM images showed that 
the morphology of the fl-siRNA PCADKe nanoparticles (fl-siRNA PKNs) and the size is 
168.8±74.7μm (Figure 2.12 A).  The uptake of fl-siRNA nanoparticles was then 
measured by flow cytometry and compared against HUVECs incubated with fl-siRNA 
complexed with 1,2-Dioleoyl-3-Trimethylammonium-Propane (DOTAP, a cationic lipid) 
(DOTAP-Fl-siRNA complexes) and free fl-siRNA.  Figure 2.12 (B) demonstrates that the 
fl-siRNA PKNs were 2-3 orders of magnitude more effective at delivering fl-siRNA into 
HUVECs than DOTAP-fl-siRNA complexes and  free-fl-siRNA.  Figure 2.12 (C) and 







Figure 2.12 Uptake of fl-siRNA PKN in HUVEC cells. (A) A SEM image of fl-siRNA 
PKNs. (B) Mean fluorescent intensity of HUVECs after treated with free fl-siRNA,  
DOTAP-fl-siRNA complex and fl-siRNA PKNs. (C) HUVECs, (D) HUVECs after 
uptaking of fl-siRNA PKNs.  
 
In vitro release of hydrophobic dyes from PCADKe microparticles 
Formulation and chacracterization of dye encapsulated PCADKe microparticles 
Various formulations and sizes of PKMs were prepared and their in vitro release 
rates were characterized and optimized. First, we showed that the speed of 
homogenization during an oil/water single-emulsion process can affect the size of 
microparticles.  The sizes and morphologies of Nile Red polyketal microparticles (NR-
PKMs) are shown in Figure 2.13. 
However, the fluorescent intensity of the Nile Red in aqueous environment was 
too low to be detected by using fluorescence spectrometry. Same problem occurred when 
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we prepare the coumarin-6 polyketal microparticles.  Among these hydrophobic dyes, 
only DiI showed detectable fluorescent intensity.  To maximize the fluorescent signal of 
DiI, we found that 0.1 % sodium dodecyl sulfate (SDS) solution can amplify the DiI 
fluorescent intensity up to 93 times (Figure 2.14). 
 
Figure 2.13 SEM images of Nile Red PCADKe microparticles prepared at different 
homogenization speeds (A) 24,000 rpm, the particle size ranges from 1 to 2 µm (6,000X 
magnification) , (B)17,500 rpm, the particle size ranges from 1 to 5 µm (1,000X 
magnification), and (C) 9,500 rpm, the particle size ranges from 2 to 10 µm (1,000X 
magnification). 
DiI-PKMs with various particle size distributions were prepared by changing the 
speed of homogenization during an oil/water single-emulsion process.  The morphology 
and sizes of the DiI-PKMs were shown in Figure 2.15.  The encapsulation efficiency of 
the DiI in the DiI-PKMs ranges from 67.8 to 83.1 %.  The in vitro release data of DiI 
PKMs showed that approximately 16 % of free DiI released in the 35 day period for the 
small particles (1.96 ± 0.64 µm) and 5 % for the larger particles (2.90 ± 1.17 µm and 5.49 
± 3.21 µm).  In general, the smaller particles (1.96 ± 0.64 µm) have faster release rates of 









































































Figure 2.14 Calibration curve of DiI in (A) PBS (pH 7.4), (B) 0.1 % SDS in PBS (pH 
7.4). The results showed that 0.1 % SDS increase the fluorescent intensity of Dil up to 92 
times (λ ex= 550 nm, λ em = 565 nm). 
 
 
Figure 2.15 SEM images of DiI-encapsulated PCADKe microparticles prepared at 
different homogenization speeds (A) 21,500 rpm, the particle size is 1.96 ± 0.64 µm 
(encapsulation efficiency:67.79 %) , (B) 13,500 rpm, the particle size is 2.90 ± 1.17 µm 
(encapsulation efficiency:82.87 %), and (C) 9,500 rpm, the particle size is 5.49 ± 3.21 




























Figure 2.16 Effects of particle size on the in vitro release of DiI from polyketal 
microparticles: 1.96 ± 0.64 µm ( ), 2.90 ± 1.17 µm( ) and 5.49 ± 3.21 µm ( ), n=5 for 
each time point. Polyketal microparticles have drug contents of 0.68 %( ), 0.83 %( ) 






New synthetic methodology can increase the molecular weight of polyketal  
In this study, we used an alternative ketal, 2,2-diethoxypropane (DEP), which has 
a boiling point of 117 oC , for this acetal-exchange reaction to alleviate the removal of the 
reactants. However, in our first few experiments, we could only slightly increase the 
molecular weight of PK3 by using the DEP method.  Thus, we speculate that there was 
still some DEP being evaporated with benzene and ethanol.  To compensate the loss of 
DEP, we added additional ketals (DEP or DMP) at 2 hours after the reaction starts.  The 
results showed a dramatic increase in molecular weight by adding additional DMP but 
not DEP.   
In this acetal exchange reaction, we used re-crystallized p-toluenesulfonic acid 
(PTSA) to increase the efficiency of the catalyst. We found that the molecular weight 
increased with minimal amount of the PTSA in the reaction, however, when the PTSA 
amount is lower than 1.5 mg, it only formed viscous liquid polymer which has low 
molecular weight.  When we increased the amount of PTSA in the reaction, the molecular 
weight of polyketals became lower.  This might be due to the extra amount of PTSA 
might accelerate the acid hydrolysis of polyketal. 
As described before, high temperature is needed to remove the byproducts 
methanol and ethanol, but it also removed the DMP and small amount of DEP, and 
resulted in low molecular weight.  To find the optimal reaction temperature for 
polymerization, the reactions were set at various temperatures (90, 95, 100 and 110 °C). 
No solid polymers were formed below 90 °C. The results suggest that the PK8 has high 
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molecular weight when the reaction was conducted at 95 °C (Figure 2.2). The reaction 
carried at higher or lower temperature than the optimization temperature generated low 
molecular weight due to either imbalance of reactants or incomplete removal of the 
byproduct. 
 
New synthetic methodology can generate solid polyketals with rapid hydrolysis 
kinetics 
Yang et al. showed that the hydrolysis kinetics of PCADK copolymers scaled 
with the amount of 1,5-pentanediol incorporated in their backbone, suggesting that the 
hydrolysis of polyketals is governed by their hydrophilicity (Yang, Bhide et al. 2008). 
Among the PCADK copolymers they synthesized using DMP method, PK3, a copolymer 
that incorporated 13 % 1,5-pentanediol and 87 % 1,4-cyclohexanedimethanol, had a 
shortest hydrolysis half-life of 2 days at pH 4.5.  By using this DEP/DMP mixture 
technique, we have developed new polyketal copolymers which can incorporate higher 
1,5-pentanediol ratios within the copolymers than PK3, thus the new polyketal 
copolymers should have fast hydrolysis kinetics than PK3. 
To investigate the hydrolysis properties of these new PCADK copolymers, we 
compared PK8 and PK10 with PK3, a polyketal polymer currently used for treating acute 
liver failure.  The hydrolysis kinetics of PK3, PK8 and PK10 were measured at the pH 
values of 5.0 and 7.4 to determine their behavior in the acidic environment of 
phagolysosomes and in the blood.  Figure 2.8 demonstrates that all the polyketal 
copolymers undergo acid-catalyzed hydrolysis, and that their hydrolysis kinetics scale 
with the amount of 1,5-pentanediol incorporated into the copolymer. For example, PK8, a 
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copolymer that incorporates 17 mole % 1,5-pentanediol and 83 mole % 1,4-
cyclohexanedimethanol, had a hydrolysis half-life of 3 days at pH 5.0.  Similarly, PK10, 
another PCADK-derived copolymer synthesized from DEP/DMP method, incorporating 
30 mole % of 1,5-pentanediol, had a hydrolysis half-life of only 2 days at pH 5, which is 
faster than PK3, which had a hydrolysis half-life of 6 days.  And also, we expect 
microparticles formulated from PK8 and PK10 are suitable for treating acute 
inflammatory diseases due to their fast hydrolysis properties. 
In general, the DEP/DMP technique did not cause any complications in the 
polymer synthesis, and could generate higher molecular weight polymers than the 
traditional method.  More importantly, all the polyketal copolymers synthesized were 
solid, and therefore have a great potential for formulation into microparticles. 
 
Modified DEP/DMP method is needed to generate high molecular weight PCADKe 
From Table 2.2, we found that the molecular weights and yields of PCADK co-
polymers were proportional to the amount of 1,4-cyclohexanedimethanol incorporated 
within the polyketal copolymers.   Thus, it is expected that using the same technique, we 
should generate high molecular PCADKe polymer.  However, the same trend was not 
observed in the synthesis of PCADK.  When we used the DEP/DMP method to 
synthesize PCADK, the reaction became very viscous after we added the additional 
DMP, consequently forming a solid bulk PCADK and halted the polymerization.  The 
resulting PCADKi (insoluble PCADK) polymer had very low solubility in both THF and 
DCM at room temperature.  The GPC results showed that the PCADKi’s molecular 
weight (Mw =6,720) was only slighter higher than the PCADK (Mw =5,345) synthesized 
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by DMP method.  The insolubility of PCADKi also caused problems for the fabrication 
of PCADK microparticle.  High temperature was needed to dissolve the PCADKi, and it 
might denature the drugs and subsequently decrease their bioactivity. 
We believe the low solubility of PCADKi is due to the increases of viscosity 
during the polymer synthesis. The relationship between molecular weight and viscosity is 
well documented.  The viscosity of polymer increases in proportional to an increase in 
molecular weight.   At higher molecular weight, the polymer become very viscous and 
difficult to mix (Rogers, Long et al. 2003). To decrease the viscosity of the reaction and 
enhance the mixing efficiency, we either added an extra volume of toluene or 
continuously added small amount of benzene to the reaction mixture.  The results showed 
that only continuously added small amount of benzene can generate high molecular 
weight PCADKe.  Although the toluene is not evaporated in this condition, the extra 
volume of toluene also diluted the concentration of the reactants and only slightly 
increased the molecular weight. 
Figure 2.6 shows that the Mw of PCADKe changes with reaction time when the 
reactions were conducted at 95 oC.  For the reaction using PTSA as a catalyst, the 
molecular weight increased with increasing reaction time to reach the maximum of 
12,000 Da at 48 hour, but decreased after that time point.  We observed the same trend 
for the reaction using PPTSA as catalyst except the highest Mw is around 9,000 Dalton 
and decreased less after 48 hour. This might be due to the moisture entering to the 
reaction while we added the benzene via the pressure equalizing funnel and cause the 
hydrolysis of polyketals.  Although the acidity of the PPTSA is milder than PTSA, the 
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efficiency of the PPTSA is lower than PTSA and resulted in low molecular weight 
PCADKe. 
 
High molecular weight PCADKe can enhance the encapsulation efficiency of drug 
One of the benefits of using high molecular weight polymers for drug delivery is 
to enhance the encapsulation efficiency and reduce the initial burst effect due to denser 
structure of the microparticles prepared from high molecular weight polymers (Jalil and 
Nixon 1990; Jaraswekin, Prakongpan et al. 2007). 
Although the high molecular weight polyketals are originally developed for 
preparation of calpain inhibitor-loaded microparticles, we also explore their drug delivery 
applications in the other therapeutics.  In collaboration with Dr. May’s group, the high 
molecular weight PCADKe was used to encapsulate AOPHA-Me, an anti-inflammatory 
drug for arthritis (Bauer, Sunman et al. 2007).  In this experiment, AOPHA-Me was 
encapsulated into two different molecular weights of PCADKe microparticles, and their 
encapsulation efficiency were compared. The encapsulation efficiency of AOPHA-Me 
into PKMs was calculated to be 3 ± 1 % (n=4) and the loading amount of AOPHA-Me 
into PKMs was 3 ± 1 μg AOPHA-Me per 1 mg of particles.  Using lower Mw PCADK, 
the loading amount of AOPHA-Me into PKMs was 0.7 ± 0.6 μg AOPHA-Me per 1 mg of 
particles (n=7).  The resulted microparticles formulated from high molecular weight 
PCADKe enhanced drug loading up to four times.  The increase of drug loading in 
polyketal microparticles agreed with the other studies that high molecular weight can 
improve the drug loading efficiency.  
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AOPHA-Me-PKMs prepared from high molecular weight PCADKe were injected 
to the rats with adjuvant induced polyarthritis.  The preliminary results showed that in 
vivo anti-inflammatory activity of AOPHA-ME-PKMs in adjuvant-induced polyarthritis 
in rats.  The paws of the positive control animals were sever swelling and paw volume 
increased, however no paw swelling were observed in the animals treated with AOPHA-
Me-PKMs (Data not shown).   
 
Molecular weight and 1,5-pentanediol incorporated ratio affect  the Tm of polyketal 
Thermal analyses of the polyketal polymers were carried out on a differential 
scanning calorimeter (DSC) and results were shown in Table 2.4.  In general, the high 
molecular weight PCADKe has a higher melting temperature (Tm) than low molecular 
weight PCADK polymer, and the PCADKe has higher Tm than PCADK copolymers.  
For example, the Tm of high Mw PCADKe is 288 oC which is 45 oC higher than the Tm 
of low Mw PCADK.  This explains why nanoparticles formulated from high Mw 
PCADKe could withstand the centrifuge force and low Mw PCADK failed, since the Tm 
is closely correlated with the mechanical property of polymer.   
The portion of non-flexible structure unit of polyketal also affects the Tm.  In 
polyketal copolymers, the Tm decreases with increasing molar ratios of 1,5-pentanediol 
incorporated.  For example, PK3, a copolymer that incorporates 13 mole % 1,5-
pentanediol and 87 mole % 1,4-cyclohexanedimethanol, had a Tm of 248 oC.  Similarly, 
PK10, a PCADK-derived copolymer synthesized from DEP/DMP method, incorporating 
30 mole % of 1,5-pentanediol, had a Tm of 98 oC, which is 150 oC lower than PK3.  The 
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only exception is the PK8 which incorporates 17 mole % 1,5-pentanediol and 87 mole % 
1,4-cyclohexanedimethanol, had a Tm of 252 oC due to its high molecular weight. 
It has been known that high molecular weight polymers have higher melting 
temperature (Tm) than low molecular weight polymer (Gopalan and Mandelkern 1967; 
Luo, Jones et al. 2002). And there are close correlation between Tm and the polymer 
properties: Polymers with high Tm present high tensile strength and high thermal 
resistance (Luo, Jones et al. 2002; Fradet and Tessier 2003).  We demonstrated that both 
high and low Mw PCADK can form nanoparticles after sonication, however only the 
nanoparticles made from high Mw PCADKe remain intact during centrifugation step 
(Figure 2.10 A) while the nanoparticles made from low molecular weight collapsed in the 
same condition (Figure 2.10 B).  We also tried to prepare nanoparticles with PK8, which 
have similar molecular weight as high Mw PCADKe, however, the PK8 nanoparticles 
also collapsed during centrifugation as low Mw PCADK nanoparticles. Both results 
suggest Tm is an important factor for the mechanic properties of polyketal polymers.  
 
High molecular weight PCADKe can fabricate nanoparticles that can be delivered 
to the endothelium cells 
Although the high molecular weight polyketals are originally developed for 
preparation of calpain inhibitor-loaded microparticles, we also found the other useful 
applications of these high molecular weight polyketals.  In our experiment, we showed 
that the high molecular weight polyketal can provide the structural stability needed for 
fabrication of nanoparticles (Figure 2.10).  Studies have shown that nanoparticles can 
enhance the drug delivery to the endothelium cells or other non-phagocytic cells (Davda 
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and Labhasetwar 2002; Thorek and Tsourkas 2008).  Since polyketal are biocompatible, 
nanoparticles formulated form polyketal could be used to target therapeutics to 
endothelium to achieve sustained therapeutic effect.  
Current applications of polyketal microparticles mainly focused on delivery of 
therapeutic agents to the Kupffer cells due to their size limitations.  Yang et al. 
demonstrated that delivery of superoxide dismutase (SOD) encapsulated polyketal 
microparticles (SOD-PKMs) can significantly reduce the TNF-α level in the serum of 
mice which were suffered from acute liver failure, however, only moderately reduce the 
Alanine aminotransferase (ALT) level, an index for liver injury (Stephen Yang, 
manuscript in preparation).  The result suggested delivery of SOD-PKMs cannot 
completely remove the extracellular superoxide that could cause heptocyte necrosis and 
liver injury.  Therefore, developing a nanoparticle delivery system that can target to the 
hepatocyte might benefit the acute liver failure therapy. 
In this experiment, we have characterized the uptake of polyketal nanoparticles by 
Human umbilical vein endothelial cells (HUVECs) in cell culture.  Figure 2.12 (B) 
demonstrates that the fl-siRNA PKNs were 2-3 orders of magnitude more effective at 
delivering fl-siRNA into HUVECs than DOTAP-fl-siRNA complexes and  free-fl-
siRNA.  The result suggested that polyketal nanoparticles can enhance the uptake in the 
endothelium cells and have the potential to delivery therapeutics to hepatocytes. 
 
Polyketal microparticles can release hydrophobic dye in a sustained manner 
The goal of my research is to formulate a polyketal microparticle delivery system 
which can sustain release of calpain inhibitors to the spinal cord.  Since AK295 is not 
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commercially available and the quantity of AK295 is limited, we have to utilize the other 
commercially available hydrophobic molecules to optimize the encapsulation and in vitro 
release kinetics.  Three different hydrophobic dyes (Nile Red, DiI and coumarin-6) were 
chosen as model compounds for the calpain inhibitors because they have similar 
hydrophobic profiles as calpain inhibitors and should have similar release kinetics 
(Figure 2.1)  
Among these hydrophobic dyes, Nile Red has the closest logP value (3.103 ± 
1.187) to AK295 (2.327 ± 0.813) and MDL-28170 (4.156 ± 0.75), and the release profile 
of Nile Red should be similar to AK295.  However, Nile Red only shows strong 
fluorescent intensity in the lipid rich environment, we were not able to detect the 
fluorescent signal in the pH7.4 phosphate buffer saline by using fluorescence 
spectrometry.  Although coumarin-6 showed strong fluorscent intensity in saline, 
however, the release rate of coumarin-6 is always low due to its hydrophobicity (logP= 
6.064 ± 0.75).  Hu et al. showed that only 5 % of courmarin 6 was released from  
coumarin-6–labeled PEG-PLA nanoparticles and have to be analyzed using HPLC (Hu, 
Li et al. 2009).  Since PCADKe is also very hydrophobic, the interaction between 
PCADKe and coumarin-6 decrease the release of coumarin-6 and we also cannot detect 
the coumarin-6 in the buffer by using fluorescence spectrometry. 
DiI have been used as neuronal fluorescent tracers for CNS delivery (Krenz and 
Weaver 1998; Shibata-Iwasaki, Dekimoto et al. 2007; Liu, Li et al. 2008).  Although it 
doesn’t have logP value, it has been genereally considered as lipidphilic or hydrophobic 
dye. When excited at 550 nm, DiI has two emission wavelengths at 565 nm, and 593 nm 
respectively.  At same concentration, the fluorescent intensity at 593 nm is two times 
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higher than the intensity at 565 nm.   However, when the DiI solution mixed with equal 
volume of 0.2 % SDS, the flouresent intensity at 565 nm increased 92 times while the 
intensity in the 593 nm only increased 16 times.  At this condition, the fluorescent 
intensity at 565 nm is three times stronger than the intensity at 593 nm , therefore we 
measured DiI concentration at 565 nm instead of 593 nm.  At 565 nm, we were able to 
detect a small amount of DiI present in the buffer and allow us to study the in vitro 
release of this hydrophobic dye. 
The size of microsphere is an important factor that affects the release rate of 
hydrophobic drugs (Dawes, Fratila-Apachitei et al. 2009). In general, smaller 
microparticle release drug faster due to an increased surface area to volume ratio.  They 
also tend to have lower encapsulation efficiency due to the loss of encapsulated drug in 
the washing steps. Budhian et al. also showed that increasing the particle size can reduce 
the initial burst effect and extend the period of release within nanoparticle formulations 
(Budhian, Siegel et al. 2008).  In our experiment, we observed the similar size effects 
when we compare the encapsulation efficiency and in vitro release of DiI of the smaller 
DiI-PKMs (1.9 μm) with the other larger DiI-PKMs.  However, when size of the DiI-
PKMs is larger than 3 μm, the size effect on encapsulation efficiency and in vitro release 
kinetics become less apparent.  From our in vitro release study, we observed that all sizes 
of DiI-PKMs exhibited different levels of incomplete release of DiI. The small 
microparticles can achieve higher cumulative release than larger particles because of their 
fast diffusion rate due to the short diffusion pathway. 
In summary, we showed that we can increase the molecular weight of polyketals 
by using a DEP/DMP method.  One of the high molecular weight polyketals, PCADKe, 
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had lowest hydrolysis rate of the polyketals, thus microparticles formulated from 
PCADKe have the potential for sustained delivery of hydrophobic compounds at pH 7.4.  
The release kinetics of polyketal microparticles (PKMs) were optimized by using a 
fluorescent dye, DiI as a model compound for calpain inhibitors, due to a similar 
hydrophobicity between DiI and calpain inhibitors (AK295 and MDL-28170), and can be 
measured by fluorescence spectrometry.  We demonstrated that microparticles based on 
high molecular weight polyketals can provide sustained release of DiI for at least one 
month. The formulation procedures developed in this chapter were used to prepare the 





PCADKe MICROPARTICLES AS A SUSTAINED RELEASE 




In this chapter, we discuss Specific Aim 2, which is to develop polyketal 
microparticles which have a release half-life of 1 month in vitro for calpain inhibitors.  
To reach this goal, we encapsulated calpain inhibitors in polyketal microparticles and 
evaluated their in vitro release kinetics and bioactivity. 
It is known that calpain activation is an important mechanism of motor neuron 
degeneration in ALS (Fischer, Culver et al. 2004), and therapeutic strategies that can 
inhibit calpain activity in the CNS have great clinical potential.  As we described in 
chapter 1, calpain inhibitors have been demonstrated to be neuroprotective in animal 
models of neurological injury, and should have great potential to treat ALS; however 
delivery problems have hindered their clinical success.  For example, AK295 is a 
hydrophobic calpain inhibitor which shows great drug properties but has low efficacy in 
vivo, due to the CNS barriers (Saatman, Murai et al. 1996).  Another potent calpain 
inhibitor, MDL-28170, can penetrate the blood brain barrier and had shown promising 
neuroprotective effects in the animal models of focal ischemic brain damage and 
Parkinson’s disease (Dong, Tan et al. 2006; Ai, Liu et al. 2007; Samantaray, Ray et al. 
2008).  However, like AK295, MDL-28170 also exhibits a dose-dependent 
neuroprotective effect (Markgraf, Velayo et al. 1998).   In order to maintain the 
concentration needed for therapeutic effects in the spinal cord, it required multiple 
injection of MDL-28170 within 48 hours (Ai, Liu et al. 2007).  In the treatment of ALS, a 
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larger delivery (volume/dose) may be needed and complications such as, infection, 
catheter obstruction, and discomfort can arise in patients when using this delivery 
method.   The other drawback of the current AK295 and MDL-28170 delivery system is 
that both drugs need to be dissolved in acidic solutions (pH 5.6) or organic solvent before 
injections (Saatman, Murai et al. 1996), which might cause some unwanted inflammatory 
effects.  Therefore, there is a great need to improve delivery systems for calpain 
inhibitors. 
In the Specific Aim 1, we demonstrated that microparticles based on high 
molecular weight polyketals can sustain the release of DiI, a hydrophobic dye for at least 
one month.  In this aim, PKMs which contain the calpain inhibitor (AK295 or MDL-
28170) were fabricated, using formulation procedures developed in Aim 1.  The size of 
AK-PKMs and MDL-PKMs were characterized by scanning electron microscopy (SEM).  
The encapsulation efficiency of AK295 in AK-PKMs was measured by liquid 
chromatography-mass spectrometry (LC-MS).  The encapsulation efficiency and in vitro 
release profile of MDL-28170 in MDL-PKMs was measured by reverse phase high 
performance liquid chromatography (HPLC).  The inhibitory activity of AK295 and 






3.2 Experimental Method 
Preparation of AK295 PCADKe microparticles (AK-PKMs) 
Briefly, 5 mg of AK295 and 50 mg of PCADKe were dissolved in 500 µL of a 
single-phase solvent (1:3 N,N-dimethylformamide : dichloromethane).  This solution was 
combined with 5 mL of 5 % poly(vinyl alcohol) (PVA) Tris buffer solution (pH=9.0) and 
the mixture was homogenized at 17,500 rpm for 1 minute.   The resulting oil-in-water 
emulsion was added to 20 mL of 1 % PVA Tris buffer solution (pH=9.0) and stirred for 4 
hours, evaporating the dichloromethane, forming particles. The resulting particles were 
washed three times in deionized water (with centrifugation at 10,000 rpm) to remove 
dimethylformamide (DMF) and PVA, and lyophilized.  Various pHs and concentrations 
of the PVA buffer were used to optimize the AK295 encapsulation.   
 
Characterizations of AK-PKMs 
The size of the AK-PKMs was characterized by scanning electron microscopy 
(SEM). Encapsulation efficiency of the AK295 in PCADKe microparticles was 
determined by liquid chromatography-mass spectrometry (LC-MS).  Briefly, 1 mg of 
AK295 PKMs were dissolved in 360 µL of sample solution (70:30:0.1 water: acetonitrile: 
trifluoroacetic acid) before analysis.  The mass transition for quantitation was set for the 
best sensitivity at m/z 505.18 to m/z 443.2 for AK295.  Various concentrations of 
AK295, and internal standard (Zlak-3001, Zlak-3002 and Zlak-3005) were used to 
establish a calibration curve.  The calculated coefficient of correlation was 0.9998 for an 





Preparation of MDL-PKMs  
Briefly, 5 mg of MDL-28170 and 50 mg PCADKe were dissolved in 500 µL of 
dichloromethane.  This solution was combined with 5 mL of 5 % poly(vinyl 
alcohol)(PVA) Tris buffer solution (pH 9.0) and the mixture was homogenized at 17,500 
rpm for 1 minute.   The resulting oil-in-water emulsion was added to 20 mL of 1 % PVA 
Tris buffer solution (pH 9.0) and stirred for 4 hours, evaporating dichloromethane and 
forming particles. The resulting particles were washed three times in deionized water 
(with centrifugation at 10,000 rpm) to remove PVA, and lyophilized. The MDL-28170 
encapsulation efficiency was optimized by formulating MDL-PKMs with various 
PCADKe with different molecular weights.  The morphology and size of MDL-PKMs 
were characterized by scanning electron microscopy (SEM).  
Characterization of MDL-PKMs by HPLC 
The encapsulation efficiency and in vitro release profile of MDL-PKMs were 
measured by reverse phase high performance liquid chromatography (HPLC). 
 
Encapsulation efficiency  
Briefly, 2-4 mg of MDL-PKMs were dissolved in 1 mL of 50 % acetonitrile, 0.1 
% trifluoroacetic acid (TFA) solution.  The resulting solution was then injected into a 
Shimadzu HPLC with an Apollo C18 Column (250 mm x 4.6 mm, 5 μm) using a linear 
gradient elution of water/acetonitrile from 80/20 to 20/80 containing 0.1 % TFA, using a 
mobile phase at 1.5 mL/min with a PDA detector set at 215 nm.  A standard curve of 
MDL-28170 was generated from 0.053 mg/mL to 0.00053 mg/mL to fit a least square 
linear regression.  Blank PKMs were also analyzed as a control. 
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In vitro release profile of MDL-28170 
Briefly, a 10 mg sample of MDL-PKMs (containing 650 µg of MDL-28170) 
(n=4) were added to a 2 mL microcentrifuge tube and suspended with 1200 µL of PBS 
(pH 7.4).  The microcentrifuge tubes were shaken at 120 rpm, 37oC.  At different time 
intervals (1, 3, 6, 12, 24 hours, 3, 7, 14, 28, and 60 days), the particle suspensions were 
centrifuged at 10,000 rpm for 15 min.  An 1100 µL volume of the supernatant was 
pipetted out and transferred to another micricentrifuge tube.  This supernatant was then 
recentrifuged at 10,000 rpm for 15 min to minimize the particles present in the solution.  
A 1000 µL volume of the supernatant was pipetted out and the same volume of fresh 
buffer was added to the tube.   
The MDL-28170 released into the supernatant was then injected into a Shimadzu 
HPLC with an Apollo C18 Column (250 mm x 4.6 mm, 5 μm) using a linear gradient 
elution of water/acetonitrile from 80/20 to 20/80 containing 0.1 % TFA, using mobile 
phase at 1.5 mL/min with a PDA detector set at 215 nm.  A standard curve of MDL-
28170 was generated from 0.053 mg/mL to 0.00053 mg/mL to fit a least square linear 
regression. At the last time point (60 days) the remaining particles were hydrolyzed and 
the amount of unreleased MDL-28170 in the particles were measured and used to 
calculate the percentage of MDL-28170 released at each time point. The supernatant 







In vitro activity assay of AK295- and MDL-28170-PKMs 
Establish a method for measuring the inhibitory activity of AK295 and MDL-28170  
The inhibition of calpain activity in response to AK295 or MDL-28170 was used 
to evaluate the bioactivity of the AK295- or MDL-29170-PKMs.  The calpain activity 
was measured by using the modified calpain assay methods described by Korukonda et 
al. and Mallya et al. (Mallya, Meyer et al. 1998; Korukonda, Guan et al. 2006).  Briefly, 
2 mg samples of AK295 or MDL-28170 were dissolved with 1 mL of DMSO.  This stock 
solution was then diluted to various concentrations of AK295 or MDL-28170 to prepare 
standard curves of AK295 and MDL-28170.  The fluorogenic substrate Suc-Leu-Tyr-
AMC for calpain I was obtained from Bachem.  Calpain I from porcine erythrocytes was 
purchased from Calbiochem.  The fluorescence was monitored using a SpectraMaxMINI 
microplate reader (Molecular Devices).   
Calpain assays were performed in a calpain assay buffer which consists of 50 mM 
Tris HCl, 50 mM NaCl, 1 mM EDTA, 1 mM EGTA, 0.1 % CHAPS, pH 7.5, 10 mM 
DTT, 5 mM CaCl2 and  0.2 μM substrate (Suc-Leu-Tyr-AMC).  A 10 μL aliquot of 
DMSO (control) or inhibitor solution in DMSO was added to 200 μL of calpain assay 
buffer.  The reaction was initiated by adding a 2 μL aliquot of Calpain I (with a final 
concentration of 10 nM) to the well.  The reaction was monitored by quantifying the 
release of 7-amino-4-methylcoumarin (AMC) (λex = 360 nm, λem = 465 nm).  Different 
concentrations of AK295 and MDL-28170 were used as the calibration standard and the 
calibration curves were plotted against the relative-fluorescence-units (RFU) increased 




Measure the bioactivity of AK295 and MDL-28170 within the PCADKe microparticles 
To extract the AK295 or MDL-28170 from the PCADKe microparticles, the 
inhibitor encapsulated microparticles (10 mg) were dissolved in 200 μL of DCM in a 4 
mL vial. After the DCM was evaporated, 1 mL of DMSO was added into the vial to 
extract the inhibitors.  The DMSO-drug solution was analyzed by HPLC (MDL-28170 
only) to determine the extraction efficiency.  A standard curve of MDL-28170 was 
generated with various concentrations of MDL-28170/DMSO solution.  
After determining the extraction efficiency, the AK295/DMSO or MDL-
28170/DMSO solutions were diluted to 2 to 20 times with DMSO.  A 10 μL of diluted 
AK295/DMSO or MDL-28170/DMSO solution was added to 200 μL of calpain assay 
buffer. The reaction was initiated by adding a 2 μL aliquot of Calpain I (with a final 
concentration of 10 nM) to the well.  The reaction was monitored by the release of 7-
amino-4-methylcoumarin (λex = 360 nm, λem = 465 nm).  The inhibitory activities of 
AK295 or MDL-28170 within the PCADKe microaprticles were calculated from the 
AK295/DMSO or MDL-28170/DMSO dilutions which fall into the correct range of the 
calibration curve.  Blank PKMs were used as a negative control in this experiment. 
 
Measure the bioactivity of AK295 and MDL-28170 released from microparticles 
A 20 mg sample of AK295 PKMs (containing 40 µg of AK295)  or MDL-28170 
PKMs (containing 1200 µg of MDL-28170) were added to a 2 mL centrifuge tube and 
suspended with 1200 μL of buffer containing 50 mM Tris-HCl (pH7.4), 50 mM NaCl, 1 
mM EDTA, 1 mM EGTA, and 0.1 % CHAPS).  The microcentrifuge tubes were shaken 
at 120 rpm, 37oC.  At various time intervals (3, 7, 14, 28 and 60 days), the particle 
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suspension were centrifuged at 10,000 rpm for 15 min.  An 1100 µL volume of the 
supernatant was pipetted out and transferred to another micricentrifuge tube.  This 
supernatant was then recentrifuged at 10,000 rpm for 15 min to minimize the particles 
present in the solution.  A 1000 µL volume of the supernatant was pipetted out and the 
same volume of fresh buffer was added to the tube.   The resulting supernatants were then 
stored in a 4 oC refrigerator until the time of testing.  For the calpain activity assay, 
DMSO was added to the supernatants to form 5 % DMSO drug containing assay 
solutions.  A 210 μL of drug containing assay solution was added to the 96 well plates. 
The reaction was initiated by adding a 2 μL aliquot of Calpain I (with a final 
concentration of 10 nM) to the well.  The reaction was monitored by the release of 7-
amino-4-methylcoumarin (λex = 360 nm, λem = 465 nm).  The inhibitory activities of 
AK295 or MDL-28170 within the PCADKe microparticles were calculated from the 
AK295/DMSO or MDL-28170/DMSO dilutions which fall into the correct range of the 




Formulation of AK295-loaded PCADKe microparticles 
The calpain inhibitor AK295 was encapsulated into microparticles using a single 
oil-in-water emulsion, solvent evaporation method.  Encapsulation efficiency of the 
AK295 in PCADKe microparticles was determined by liquid chromatography-mass 
spectrometry (LC-MS).  As shown in Figure 3.1, both free AK295 (A) and AK295-
PCADKe particles (B) showed a strong intensity of the AK295 ion fragments at m/z 
505.18 to m/z 443.2.   
 
Figure 3.1 Representative chromatogram of (A) AK295 standard solution, (B) blank 
PCADKe microparticles, and (C) AK295-encapsulated PCADKe particles from LC-MS. 
(Courtesy from Christina Hampton from Dr. Fernandez’s Lab.)  
In contrast, the intensity of the same fragment in the blank PCADKe 
microparticles was about 200 times lower than the free AK295 and AK295-encapsulated 
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PCADKe microparticles.  This indicates that LC-MS technique is suitable for measuring 
the amount of AK295 encapsulated in the PCADKe particles.  
 
Table 3.1 Encapsulation efficiency, and particle sizes of various AK295 encapsulated 
polyketal microparticles 




PVA buffers E.E.* 
(%) 
Particle Size  
(nm) 
AK-PKM1 Yes 13,500 5.0 % PVA in Tris-NaCl 5.08 5542 ± 1837
AK-PKM2 Yes 21,500 5.0 % PVA in Tris-NaCl 0.64 1064 ± 156 
AK-PKM3 No 21,500 5.0 % PVA in Trisl 2.67 2344 ± 448 
AK-PKM4 No 21,500 1.0 % PVA in Trisl 1.03 2173 ± 662 
AK-PKM5 No 21,500 0.4 % PVA in Trisl 0.82 5750 ±1445 
AK-PKM6 No 21,500 5.0 % PVA in Tris-NaCl 1.85 1676 ± 366 
AK-PKM7 No 21,500 1.0 % PVA in Tris-NaCl 17.7 4895 ± 2379





Figure 3.2 SEM images of AK-PKMs. (A) AK-PKM1, (B) AK-PKM2, (C) AK-PKM3, 




Characterizations of MDL-28170 PKMs 
The calpain inhibitor MDL-28170 was encapsulated into microparticles using a 
single oil-in-water emulsion, solvent evaporation method.  Encapsulation efficiency of 
the MDL-28170 in PCADKe microparticles was determined by reverse phase HPLC.  As 
shown in Figure 3.3, both MDL-28170-PKMs (A) and free MDL-28170 (B) showed a 
strong peak around 15 min.  In contrast, the intensity of the same fragment in the blank 
PCADKe microparticles was about 1,000 times lower than the free MDL-28170 and 
MDL-PKMs.  This indicates that reverse HPLC technique is suitable for measuring the 
amount of MDL-28170 encapsulated in the PCADKe microparticles.  
MDL-PKMs were prepared from three different molecular weights of PCADKe to 
maximize the MDL-28170 encapsulation efficiency. The morphology and sizes of these 
MDL-PKMs were characterized by SEM and DLS.  Figure 3.4 shows the SEM images of 
MDL-28170-loaded PCADKe microparticles and demonstrate that their size ranges from 
1 to 2 μm.    The MDL-28170 encapsulation efficiency varies between 43.5 to 76.8 %. 
The results of encapsulation efficiency and particles size of MDL-PKMs were shown in 
Table 3.2. In general, the encapsulation efficiency and particles size of MDL-PKMs 





Figure 3.3 Representative chromatogram of (A) MDL-28170-encapsulated PCADKe 
particles (B) MDL-28170 standard solution, and (C) blank PCADK microparticles from 
reverse phase HPLC. 
 
 







Table 3.2 Encapsulation efficiency and particle size of MDL-PKMs 
MDL-PKMs Molecular weight (Mw) 





1 6,317 43.5 1.23 ± 0.36  
2 9,623 56.3 1.05 ± 0.19 
3 12,234 76.8* 2.02 ± 0.64 
* The encapsulation efficiency of MDL-28170 in the PCADKe microparticles was 
determined by reverse phase HPLC at 215 nm. 
Encapsulation efficiency (%) = (amount of MDL-28170 loaded in microparticles) / 
(initial amount of MDL-28170 used to make microparticles) x 100  
** Particle size was determined by dynamic light scattering (DLS) 
 
In vitro release profile of MDL-28170 from MDL-PKMs 
In order to determine whether or not MDL-PKMs have suitable properties for 
sustained delivery of MDL-PKMs in a physiological environment, we investigated the in 
vitro release kinetics of MDL-PKMs in pH 7.4 phosphate buffer saline by using high 
performance liquid chromatography (HPLC).  The release profile of MDL-28170 from 
PCADKe microparticles is shown in Figure 3.5.  We observed a burst release within the 
first 3 days (16 %).  Approximately 50 % of the MDL-28170 was released in the first 30 
days and slowly released until Day 55.  The morphology of the MDL-PKMs changed 
after drug release.  At Day 55, the large MDL-PKMs still retain their size, however, they 
become porous when compare to the MDL-PKMs day 1.  We also observed that most of 
the small MDL-PKMs completely lose their structure and become amorphous hydrolyzed 




Figure 3.5  Release kinetics of MDL-28170 encapsulated in PCADKe microparticles 
(n=4 for each time point) 
 
 






Measure the bioactivity of AK-PKMs and MDL-PKMs 
The inhibition of calpain activity in response to AK295 or MDL-28170 was used 
to evaluate the bioactivity of the AK-PKMs or MDL-PKMs.  The calpain activity was 
measured by using the modified calpain assay methods described by Korukonda et al. 
and Mallya et a.l (Mallya, Meyer et al. 1998; Korukonda, Guan et al. 2006).  The calpain 
activity was measured by monitoring the release of 7-amino-4-methylcoumarin (λex = 360 
nm, λem = 465 nm).  Different concentrations of AK295 and MDL-28170 were used as 
the calibration standard and the calibration curves were plotted against the RFU increased 
amounts for different concentrations of calpain inhibitors.  The calibration curve for 
AK295 is shown in Figure 3.7 and the calibration curve for MDL-28170 is shown in 
Figure 3.8.  From these calibration curves, the calpain inhibitory activity of the AK-
PKMs and MDL-PKMs was calculated.   The inhibitory activity of encapsulated calpain 
inhibitors was determined by dividing the concentration of active calpain inhibitor of the 
microparticles with the total amount of calpain inhibitors encapsulated within the 
microparticles.  The inhibitory activity of the calpain inhibitors from AK-PKMs and 
MDL-PKMs were summarized in Table 3.3. The released buffers from AK-PKMs and 


































Figure 3.7 Inhibitory activities of AK295 were determined by establishing a calibration 
curve.  The inhibitory effect of AK295 was determined by measuring the fluorescent 





































Figure 3.8 Inhibitory activities of MDL-28170 were determined by establishing a 
calibration curve.  The inhibitory effect of MDL-28170 was determined by measuring the 
fluorescent intensity of AMC released from calpain substrate(λex = 360 nm, λem = 465 
nm) 
 
Table 3.3 Calpain inhibitors loading, encapsulation efficiency and inhibitory activity in 
PCADKe microparticles form AK295-PKMs and MDL-28170-PKMs. 
 AK295-PKMs MDL-28170-PKMs 
Encapsulation Efficiency 2.69 % 56.3 % 
Calpain inhibitor loading 
by weight 
0.25 μg AK295 per mg of 
AK-PKMs 
5.12 μg MDL-28170 per mg of 
MDL-PKMs 
Calpain inhibitor activity 19.58± 3.41 % 72.75± 9.58 % 
Active Calpain inhibitors 
loading by weight 
48.96 ng of active AK295 per 
mg of AK-PKMs 
3725 ng of active MDL-28170 




Because of the ongoing nature of ALS, sustained delivery of calpain inhibitor to 
the motor neurons is needed to enhance the therapeutic effects.  Both AK295 and MDL-
28170 showed a dose-dependent neuroprotective effect (Markgraf, Velayo et al. 1998).  
To achieve the desired therapeutic effect, it requires delivery of sufficient amount of 
active calpain inhibitor to the spinal cord.  Therefore, it is important to establish a method 
to quantify the calpain concentration in the calpain encapsulated polyketal microparticles.  
Because AK295 and PCADKe show a sever overlapping between their absorption 
spectra, we have tried to separate them by reverse phase HPLC.  AK295 showed a broad 
peak from 4.0 to 5.8 min and a sharp peak at 6 min (Figure 3.9 A) and PCADKe 
microparticle had a sharp peak from 5.2 to 5.6 min (Figure 3.9 B), thus we should be able 
to differentiate the AK295 and PCADKe microparticles.  However, the peak of PCADKe 
microparticles is seven times higher than the peak of AK295 at 6 min, it is very difficult 
to quantify the AK295 by HPLC when the AK295 concentration is low (Figure 3.9 C).  
In collaboration with Dr. Fernandez’s lab at Georgia Tech, we were able to quantify the 
encapsulation efficiency of AK295 by using LC-MS.  The results showed that LC-MS 
can detect AK295 at very low amount (pg), and is suitable for quantification of AK295 in 
the AK-PKMs.  The results showed that the encapsulation efficiency of AK-PKM1 was 
5.08 %, however, AK-PKM1 is not suitable for intraspinal cord injection due to their 
size.  In our preliminary study, we injected various sizes of Nile Red microparticles to the 
wild type animals.  We found the delivery efficiency drastically decreased when the Nile 
Red microparticles was larger than 3 μm.  However, the encapsulation efficiency 
decreased to 0.6 % as the particle size dropped to 1-2 μm. Several parameters including 
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with or without DMF in organic phase, PVA concentration of 0.2 to 5 % as stabilizer, and 
the salt in PVA solution were examined to optimize the formulations (Table 3.1 and 
Figure 3.2).  
 
Figure 3.9 Representative chromatogram of (A) AK295, (B) Blank PCADKe 
microparticles and (C) AK295-encapsulated PCADKe microparticles from reverse phase 
HPLC. 
  
Generally, porous microparticles, which were prepared from DMF-DCM solution, 
have lower AK295 encapsulation efficiency than non-porous microparticles in same size 
range. The removal of the DMF during particle preparation created porous structures in 
AK-PKMs.  This porous structure allowed the water to enter into the center of the particle 
and increase the loss of AK295 during the washing steps. 
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Several studies have shown that decrease in the concentration of surfactant can 
increase the encapsulation efficiency (Esmaeili, Atyabi et al. 2008; Guo and Chu 2008), 
however, it also increases the particle size.   In our experiment, we observed the similar 
effect on the size of AK-PKMs, however, the effect of surfactant on encapsulation 
efficiency was not clear.  In general, AK295 encapsulation efficiency is higher as the 
particles size increase, and the particle size distribution of AK-PKMs is narrower when 
they were prepared from the Tris buffer without NaCl. 
 Due to the low encapsulation efficiency of AK295, we decided to encapsulate 
another calpain inhibitor MDL-28170 as an alternative therapeutic agent because it has 
lower Ki value (8 nM) than AK295 (41 nM) and can be quantified by reverse phase 
HPLC (Figure 3.3). The MDL-28170 encapsulation efficiency in PCADKe 
microparticles ranges from 43.5 to 76.8 %, which is 16 to 29 times higher than AK295.  
The high encapsulation efficiency mainly due to its hydrophobicity (logP = 4.156 ± 
0.705).  
 We also observed that microparticles prepared from high molecular weight 
polyketals resulted in higher encapsulation efficiency of MDL-28170 and larger particle 
size (Table 3.2).  Ziberman et al. showed that as the molecular weight of PLGA 
increases, the viscosity of the organic phase also increases and subsequently increases the 
sizes of microparticles (Zilberman and Grinberg 2008).  As we described in Chapter 1, 
the encapsulation efficiency is higher in the larger particle. This might explain the 
increase of encapsulation efficiency in the polyketal microparticle formulated from high 
molecular weight PCADKe.   
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The in vitro release profile of MDL-PKMs at pH 7.4 PBS was shown in Figure 
3.5. We observed a burst release within the first 3 days (16 %).  Approximately 50 % of 
MDL-28170 released in the first 30 days and slowly released until Day 55.  The in vitro 
release profile of MDL-28170 is similar to the other release profile of hydrophobic 
compound from polymeric microparticles which undergo bulk erosion.  
To investigate whether polyketal microparticles undergo bulk erosion, we also 
performed an experiment to investigate the degradation of the polyketal microparticles by 
observing their morphology changes using SEM.  The SEM pictures showed that the size 
of the MDL-PKMs ranges from 0.5 to 1.5 μm at Day 0 (Figure 3.6 A).  After releasing 
drug into PBS for 60 days, the size of larger MDL-PKMs (ranges from 1 to1.5 μm) 
remained unchanged however, the structure of MDL-PKMs become porous.  In the mean 
time, small MDL-PKMs (under 1 μm) collapsed and became amorphous hydrolyzed 
polymer (Fugure 3.6 B).  We hypothesized that MDL-PKMs undergoes bulk erosion 
mechanism, because we didn’t observe significant change in the size of MDL-PKMs 
after incubation with PBS for 60 days.  The bulk erosion mechanism might undergo the 
following scenarios. Upon contact with PBS water diffused into MDL-PKM and the 
MDL-28170 diffused out of MDL-PKMs due to the concentration gradient.  In the same 
time, the polyketal was hydrolyzed and cleaved into short chains.  The porous structure of 
DML-PKMs was created by the removal of MDL-28170 and hydrolyzed polyketal.   For 
the smaller MDL-PKMs (under 1 μm), water can rapidly diffuse to the center of the 
particle due to the short distance between surface and center of the small microparticles.  
And subsequent hydrolysis in the particles leads to collapse of the microparticles.   Our 
hypothesis was supported by the research done by von Burkersroda et al (von 
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Burkersroda, Schedl et al. 2002).  In their study, polyketals will undergo bulk erosion 
when the polymer devices are smaller than 400 µm.   
The goal of my thesis is to deliver therapeutic levels of calpain inhibitors into the 
spinal cord, therfore it is important to verify the activity of these calpain inhibitors.  In 
order to estimate accurate amount of active drug delivered into the animals, it is essential 
to establish a reliable method to measure the calpain activity within the particles. The 
HPLC results showed that 95 % of the MDL-28170 was extracted from MDL-28170 
PKM by this extraction method.  Since AK295 is less hydrophobic than MDL-28170, we 
expect the same or higher extraction efficiency (> 95 %) for AK295.  
The activity of AK295 and MDL-28170 encapsulated in PKMs was shown in 
Table 3.3.  The results showed that 73 % of the encapsulated MDL-28170 maintained 
activity, while only 20 % of the AK295 remains active after formulation of the 
microparticles.   Combining the results of activity assay with previous encapsulation 
efficiency data; the amount of active MDL-28170 in PCADKe microparticles is 75 times 
higher than the amount of active AK295 in the PCADKe microparticles.  However, 
AK295 might have a higher retention time in the spinal cord due to its poor BBB 
permeability.   Therefore both AK295 and MDL-28170 should have potential to success 




IN VIVO EVALUATION OF CALPAIN INHIBITORS-
ENCAPSULATED PCADKe MICROPARTICLES 
 
4.1 Introduction 
In Specific Aim 3, the objective was to evaluate the in vivo performance of drug 
containing PCADKe microparticles in the spinal cord. The high molecular weight 
PCADKe microparticles are designed to deliver calpain inhibitors (AK295 and MDL-
28170) to the L1-L2 lumbar cord of rat, where the calpain inhibitors will inhibit the 
calpain activation and slow down the progress of motor neuron death. 
Our working hypothesis was that calpain inhibitors-encapsulated polyketal 
microparticles will deliver therapeutic levels of calpain inhibitor to the spinal cord and 
extend the period of calpain inhibitors release to two months after an intraspinal cord 
injection. 
Two calpain inhibitors, AK295 and MDL-28170 were used in this study to 
increase the potential for success. AK295 is a hydrophobic calpain inhibitor, which 
shows great drug properties but has low efficacy in vivo, due to the presence of the highly 
impermeable blood brain barrier (BBB) and blood spinal cord barrier (BSCB). Another 
potent calpain inhibitor, MDL-28170, can penetrate blood brain barrier and had 
promising neuroprotective effects in the animal models of focal ischemic brain damage 
and Parkinson’s disease.  However, like AK295, MDL-28170 also exhibits a dose-
dependent neuroprotective effect.   In order to maintain the concentration needed for 
therapeutic effects in the spinal cord, it requires high dose.  In the treatment of ALS, a 
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larger delivery (volume/dose) may be needed and complications can arise from the 
delivery method used such as, infection, catheter obstruction, and discomfort to the 
patient when using this delivery method to treat humans. 
To test our hypothesis, we first investigated the fate of the microparticles after an 
spinal cord injection by studying the distribution of the dye-encapsulated PKMs in 
Sprague Dawley rats. Then we evaluated the efficacy of calpain inhibitor-encapsulated 
PKMs by evaluation of behavior studies and survival of SOD1G93A rats, a genetic rat 
model for ALS (Howland, Liu et al. 2002; Matsumoto, Okada et al. 2006). 
The dye encapsulated PKMs (Nile Red PKMs, DiI-PKMs and coumarin-6 PKMs) 
formulated in Aim 1 were used to study the fate of the polyketal microparticles after 
intraspinal cord injection.  The distribution of the microparticles was measured by 
fluorescence microscopy.  The AK-PKMs and MDL-PKMs formulated in Aim 2 were 
used to investigate the in vivo activity of calpain inhibitors in the spinal cord tissue.  In 
this specific aim, either AK-PKMs (n = 8), MDL-PKMs (n = 8), or PBS (n = 6) was 
injected into the lumbar enlargement, L1-L2, of SOD1G93A rats.  For each SOD1G93A rats, 
5 μL of either 50 mg/mL AK-PKMs, 50 mg/mL MDL-PKMs, or PBS was injected into 
both hemispheres of the spinal cord at 70 days, which precedes symptom onset.  Disease 
progression was monitored by weekly assessment of weight loss, grip strength, rotarod 
performance, and ALS motor score. The survival curve of ALS animals was generated 
with a Kaplan-Meier method.  
These experiments were conducted in collaboration with Dr. Boulis’s laboratory 
in Emory.  Dr. Michele Kleim, Dr. Bethwel Raore, Dr. Colin Franz, Ms. Jing Ma, Ms. 
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Christina Krudy and Mr. Brenten Heeke made significant contributions to the in vivo 
experiments present in this Chapter. 
 
4.2 Experimental Methods 
Animal models 
Experiments were performed on two strains of rat. Sprague Dawley wild-type rats 
were purchased from Charles River Laboratories (Whilmington, WA).  The SOD1G93A 
rats, which were transgenically engineered to express the human Cu+2/Zn+2 superoxide 
dismutase 1 gene with a glycine to alanine base pair mutation at its 93rd codon. The 
founders for the SOD1ALSG93A colony were obtained from Taconic Farms (Germantown, 
NY) and bred locally. Four week from the breeding date, the SOD1G93A litters were 
genotyed. This process was used to generate a homologous population by exclusion of 
animals with abnormally high or low SOD1 copy numbers. Genotyping was performed 
by PCR as previously described (Howland, Liu et al. 2002). All procedures were 
approved by the Institutional Animal Care and Use Committee of Emory University. 
 
Determine the fate of PKMs after intraspinal cord injection 
Three hydrophobic fluorescence dyes (Nile Red, DiI and coumarin-6) were 
encapsulated in PCADK in order to study the fate of PKMs after intraspinal cord 
injection.  The NR-PKMs with three different size distributions (1-2 μm, 1-5 μm, and 2-
10 μm) and other dye encapsulated PKMs were prepared by a single emulsion technique 
as described in chapter 2.  The sizes of the dye encapsulated PKMs were determined by 
SEM and DLS.   
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Intraspinal cord injection 
The intraspinal cord injection procedure is modified from the method described 
by Franz et al.(Franz, Federici et al. 2009). Briefly, 120 µL of phosphate buffer saline 
(pH 7.4) was added to a 500 µL microcentrifuge tube containing 6 mg of NR-PKMs.  
The mixture was sonicated and vortexed to form a NR-PKM suspension (50 mg/mL).  10 
µL of this NR-PKM solution was directly injected into L1-L2 lumbar spinal cord of adult 
Sprague Dawley rats (n=2) to study the fate of PKMs after intra-spinal cord injection.  In 
order to achieve direct access to the spinal cord, the paraspinous muscles were elevated 
from the lamina and spinous processes, and then a T13 laminectomy were performed 
(note: the T13 vertebrate corresponds to the L1-4 spinal cord segments).  A volume of 5 
µL of NR-PKMs (50 mg/mL) was injected bilaterally at both sites of L1-L2 or a total 
injection volume of 10 µL per rat.  In order to perform the injection a micropipette pulled 
to an approximately 100 µm diameter were mounted on a nanoject oocyte injector 
apparatus (Drummond Scientific).  The pipette then were positioned over the dorsal root 
entry zone and advanced into the parenchyma using a micromanipulator.  NR-PKMs 
were slowly infused with 50 nL boluses spread over 20 minutes.  To minimize the reflux 
of the NR-PKMs, the pipette was left in place for at least 1 minute following the last 
injection of each site. The animals were euthanized at day 1, day3, day 14 and 1 month 
after NR-PKMs injection.  
Coumarin-6-PKMs (1-2 μm) and DiI-PKMs (1-2 μm) were injected to the 
Sprague Dawley rats via the same procedure as NR-PKMs, except we only injected the 
dye encapsulated PKMs with a single particle size distribution.  Since DiI-PKMs had 
strong signals under the both optical and fluorescent microscopes, we included more 
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animals in this group.  The animals receiving DiI-PKMs were sacrificed at 3 hours, day 7 
and day 14. 
 
Histology 
At the time of sacrifice, spinal cords were fixed in phosphate buffer saline 
containing 4 % paraformaldehyde overnight. The spinal cords were dissected and placed 
in 30 % sucrose solution overnight and preserved in optimized cutting temperature 
compound (OCT) for cryosectioning.  The spinal cords were coronally sectioned into 30 
μm samples and mounted on positive charged plus slides and stored in a -20 oC freezer 
until fluorescent microscopy. The frozen sections were analyzed by fluorescence 
microscopy to determine the locations and distribution of the dye-encapsulated PKMs. 
 
In vivo performance of calpain inhibitor encapsulated microparticles  
To investigate the in vivo performance of the calpain inhibitor encapsulated 
PKMs, AK-PKMs or MDL-PKMs were directly injected into L1-L2 lumbar spinal cord 
of SOD1G93A rats.  Three experimental groups:  a) AK295-PKMs (n=8); b) MDL-28170-
PKMs (n=8) and c) phosphate buffered saline (n=5) were used in this study. Drug (and 
vehicle) effects on behavior, survival and motor neuron counts were evaluated.  All tests 
and surgery were done in a double-blind fashion. 
 
Intraspinal cord injection 
AK295-PKMs (n = 8), MDL-28170-PKMs (n = 8), or PBS (n = 5) was injected 
into the lumbar enlargement, L1-L2, of SOD1G93A rats, a genetic rat model for ALS. For 
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each rat, 5 μL of 50 mg/mL AK295-PKM or 50 mg/mL MDL-28170-PKM, or PBS was 
injected into both hemispheres of the spinal cord at 70 days, which precedes symptom 
onset.   
 
Behavior study 
No earlier than one week prior to intraspinal cord injection surgery, baseline 
behavior measurements were performed to assess motor function. Following surgery, rat 
underwent behavior testing 1-2 times per week until reaching experimental end-stage. 
Disease progression was monitored by weekly assessment of grip strength, rotarod 
performance, ALS motor score (Howland, Liu et al. 2002; Matsumoto, Okada et al. 2006) 
and Basso, Beattie, Bresnahan Locomotor Rating Scale (BBB scale) (Howland, Liu et al. 
2002; Matsumoto, Okada et al. 2006).  The grip strength measurements were made with a 
Chatillon Digital Force Gauge DFIS-2 (Ametek Inc.), and the best of 5 trials was 
recorded. An Eonomex accelerating rotarod (Columbus Instruments, Columbus, OH) was 
used to analyze motor coordination and balance. The test was performed beginning at 5 




Animals were weighed weekly from the week of intraspinal cord injection surgery 






ALS was allowed to progress until the animal showed signs of morbidity (ALS 
motor score 0, the rat was unable to right itself from either side), at which point 
interventional euthanasia was administered. Time of death was determined to be the 
following date. The survival curve was statistically analyzed with Kaplan-Meier method.  
 
Motor neuron analysis 
At the time of sacrifice, spinal cords were fixed in phosphate buffer saline 
containing 4 % paraformaldehyde overnight. The spinal cords were dissected and placed 
in 30 % sucrose solution overnight and preserved in optimized cutting temperature 
compound (OCT) for cryosectioning.  The spinal cords were coronally sectioned into 30 
μm samples and mounted on positive charged plus slides and stored in a -70 oC freezer. 
The quantification of the motor neuron density and size was performed on a 30 μm thick 
sections of L1-L2 spinal cord with Nissl stain.   
Nissl staining was used for the detection of Nissl body in the cytoplasm of 
neurons, and can be used to identify the basic neuronal structure in spinal cord tissue. 
Briefly, the spinal cord frozen sections were rehydrated by placing the slides through 100 
% and 95 % alcohol to distilled water to reduce the background fat staining.  The slides 
then were stained in crystal violet solution (Fisher, USA) for 20-30 minutes.  The slides 
were rinsed quickly in distilled water. The slides were dehydrated through 95 % and 100 
% for 5 minutes. The slides then again were placed in 100 % alcohol and checked 
microscopically for the best result. The slides were placed in Histo-Clear® solutions for 5 
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minutes to remove the extra crystal violet, and mounted with permaslip mounting 
medium and liquid (Alban Scientific Inc, St Lous, MO). 
The ventral horns of each sample were captured using a Nikon Eclipse E400 
microscope and Nikon DS-Fi1 CCD camera.  The area of ventral horn neurons was 
measured with NIS Elements Imaging BR, SP3 Hotfix 4 (Build 473) image analysis 
software (Nikon Instruments Inc). Nissl positive cells were considered to be motor 






Distribution of hydrophobic dye-loaded PCADKe microparticles in the spinal cord 
To evaluate the fate of PCADKe microparticles after intraspinal cord injection, 
NR-PKMs, DiI-PKMs and comarin-6-PKMs were injected to ventral horn of L1-L2 
spinal cord of Sprague Dawley rats.  In our first experiment, we found only small NR-
PKMs (1-2 μm) could easily pass the needle tip of nanoinjector.  The animals that 
received NR-PKMs were euthanized at day 1, day 3, day 14 and 1 month after intraspinal 
cord injection.  However, the fluorescent of the NR-PKMs or released Nile Red were not 
detected in the spinal cord. 
The fluorescent images of DiI-PKMs and coumarin-6-PKMs were taken from the 
spinal cord of rat at L1-L2.  As shown in Figure 4.1 A, DiI-PKMs and coumarin-6-PKMs 
showed strong signals in the spinal cord of rat, and both particles were confined in the 
injection area three hours after implantation.  
A B
 
Figure 4.1 Distribution of the (A) DiI-PKMs, (B) coumarin-6-PKMs in the spinal cord. 
 
We took another image of the distribution of the DiI-PKMs in the spinal cord at 
Day 7.  As shown in Figure 4.2, merged images of DAPI and DiI-PKMs revealed that 
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most of the DiI-PKMs stayed in ventral horn of L1-L2 spinal cord of rat and did not get 




Figure 4.2 Distribution of DiI loaded PCADKe microparticles in the spinal cord. (A) the 
nuclei were stained with DAPI to visualize the structure of spinal cord section (B) DiI-
PKMs distribution in the L1-L2 spinal cord, (c) merged images of DAPI and DiI-PKMs 
(10 X) (D) merged images of DAPI and DiI-PKMs (2 X) 
 
Behavior studies of ALS rats  
We started the behavior studies with three experimental groups consisting of 8 
rats each:  a) AK-PKMs; b) MDL-PKMs and c) saline control.  However, three animals 
were removed from the control group.   One control animal died during surgery and the 
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other two control animals were excluded due to its light weight or for not showing 
progression of ALS. 
 
ALS motor score 
ALS motor scale proposed by Matsumoto et al. (Matsumoto, Okada et al. 2006) 
was used to determine the stage of ALS of SOD1G93A rats in our experiment.  In their 
paper, the rats with different progression of ALS were divided into six groups by giving 
them scores between 0 and 5. The detail testing procedure for the ALS motor score is 
described in their paper (Matsumoto, Okada et al. 2006).  Briefly, a rat without any 
observable function deficits were given a score of 5 (normal) and a rat with any 
observable function deficits was given a score of 4 (onset of ALS).  And a rat cannot 
right itself within 30 sec was given a score of 0 (end point).  
For our in vivo experiment, all animals in all groups started with a motor score of 
5.  Each month represents 3 weeks of measurements.  At baseline (BL), we have a total of 
21 rats (AK-PKMs, n=8; MDL-PKMs, n=8; and saline control, n=5).  Time plots of ALS 
motor scores show all the animals began to onset the disease around 91 to 112 days, and 
show no differences in the progression of muscle weakness in animals of AK-PKMs and 





































Rough estimates of the 
ages of rats (Days)
Injection = 70
Month 1 = 91
Month 2 = 112
Month 3 = 133
Month 4 = 154
Month 5 = 175
Month 6 = 196
Month 7 = 217
 
Figure 4.3 Comparison of disease progression by (A) ALS motor score   (B) BBB score. 
 
Basso, Beattie, Bresnahan locomotor rating 
The Basso, Beattie, Bresnahan Locomotor Rating Scale (BBB scale) has become 
a golden standard for assessing hindlimb motor function after spinal cord injury (SCI) in 
rat (Basso, Beattie et al. 1995; Magnuson, Trinder et al. 1999).  In recent years, BBB 
97 
 
scale also has been used to estimate the locomotor function of ALS rat model (Suzuki, 
Tork et al. 2007).  
To compare the locomotor function of ALS rats between each experimental 
group, we evaluated these ALS rats by following the guideline of 21-point BBB scale 
proposed by Basso et al. (Basso, Beattie et al. 1995; Basso, Beattie et al. 1996). If a rat 
displayed no signs of movement was given a score of 0 (end point). And the rat with 
normal locomotion was given a score of 21 (normal). Time plots of BBB open field 
scores show no differences in the progression of muscle weakness in animals of AK-
PKMs and MDL-PKMs compared to the animals that received saline (Figure 4.4 B). 
 
Hindlimb grip strength and rotarod treadmill performance 
The results of the hindlimb grip strength and rotarod treadmill performance were 
shown in Figure 4.4.  We observed the average grip strength of both AK-PKMs and 
MDL-PKMs treated animal are slightly higher than the control animal in the first four 
months post injection, however, there is no statistical differences between each group.  
We observed the same trend in the rotarod treadmill performance test, but again, it is 




































































Rough estimates of the 
ages of rats (Days)
Injection = 70
Month 1 = 91
Month 2 = 112
Month 3 = 133
Month 4 = 154
Month 5 = 175
Month 6 = 196
Month 7 = 217
 































































Weight loss of ALS rat also can be used to monitor the progression of ALS.  
Masutomo et al showed that the peak of weight loss can be used as an index of “pre-
symptomatic” disease onset, which is approximately 13 days prior to the symptomatic 
onset.  The results of weight loss of each experimental group are shown in Figure 4.5 A.  
The bodyweights of ALS rat peaked between month 3 and 4 (between day 133 and 154).   
In our experiment, the peak of the weight was very close to the disease onset, which is at 




The therapeutic effects of AK-PKMs and MDL-PKMs treatment were determined 
by comparing the respective survival times in response to treatment type.  Kaplan-Meier 
survival curves were generated for each experimental group. As shown in Figure 4.5 B, 
no significant differences were observed in all the groups.  The mean survival (± SE) was 
not increased by AK-PKMs (188.25 d ± 17.52) or MDL-PKMs (179.5 d ± 4.16) delivery 
to ALS rats relative to saline injected control (182.8d ± 16.07). 
 
Motor neuron assay 
Both AK295 and MDL-28170 are potent calpain inhibitors and have shown 
promising neuroprotecive effects in the animal models of focal ischemic brain damage.  
However, the effect of calpain inhibitor therapy has not been studied in SOD1G93A rat 
model.  To study the effect of calpain inhibitors on the protection of motor neurons, we 
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investigated the efficacy of the AK295 and MDL-28170 by injecting the AK-PKMs and 
MDL-PKMs into the L1-L2 ventral horn in SOD1G93A rat.  After the rats were sacrificed 
at endpoint, the spinal cords were sectioned and stained with Nissl staining agents to 
visualize the (Figure 4.6). Nissl positive cells were considered to be motor neurons if 
their soma was greater than 300 μm2 in area. The motor neuron density and soma area 
were analyzed and the results were shown in Figure 4.7.   The mean (± SE) cell density of 
motor neurons counted in ventral horns of AK-PKMs treated group was 19.27 ± 8.03 
(n=2).  This was more motor neuron than the MDL-PKM treated group (4.79, n=1) and 
saline control group (11.08 ± 2.51, n=3).  The results showed that animals that received 
AK-PKMs have higher motor neuron density than the saline control and MDL-PKMs 
treated animals, however more animal numbers are required to get statistically 
differences.  We also calculated the mean area of motor neuron, but found no differences 
between any of the treatment groups.   
 
Figure 4.6 Nissl stain of spinal cord 
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This is the first study to examine the efficacy of calpain inhibitor therapy in the 
SOD1G93A rats by intraspinal injection of calpain inhibitor-loaded microparticles.  It is 
known that calpain activation is an important mechanism of motor neuron degeneration 
in ALS (Fischer, Culver et al. 2004), and therapeutic strategies that can inhibit calpain 
activity in the CNS have great clinical potential.  As we described in chapter 1, calpain 
inhibitors have been demonstrated to be neuroprotective in animal models of neurological 
injury, and should have great potential to treat ALS; however delivery problems have 
hindered their clinical success.  Because of the ongoing nature of ALS, sustained delivery 
of calpain inhibitor to the motor neurons is needed to enhance the therapeutic effects.  In 
previous chapter, we have confirmed that MDL-PKMs can continuously release MDL-
28170 for 55 days in vitro.   In this study, we delivered the AK-PKMs and MDL-PKMs 
to the spinal cord of SOD1G93A rats via intraspinal cord injection.  The microparticles 
serve as a depot for AK295 and MDL-28170, and continuously release these them to 
inhibit the abnormal calpain function in the motor neurons.  The in vivo efficacy of AK-
PKMs and MDL-PKMs were tested by evaluating the behavior, survival study of 
SOD1G93A rats and their histology at the end stage.  We observed that AK-PKMs can 
enhance the performance of behavior study in the early stage.  Animals treated the AK-
PKMs have longer survival time and higher motor neuron density than those treated with 






Intraspinal cord delivery of microparticles 
Our objective in this study was to demonstrate that PCADKe microparticles could 
be injected into the spinal cord and serve as a delivery system for calpain inhibitor, which 
can protect motor neurons and stop the progression of ALS.  
The initial experiments were conducted using dye-encapsulated microparticles to 
optimize the injection technique and study the fate of the microparticles after intraspinal 
cord injection.  These results suggest only particles smaller than 1-2 μm can be delivered 
to the spinal cord by using a nanoinjector system.  As discussed in chapter 2 and 3, the 
size of the microparticles plays a major role in the encapsulation efficiency and release 
profile.  More dyes or calpain inhibitors can be loaded into a larger particle since less 
amount of dye or calpain inhibitors are washed out or diffused out.  The other advantage 
of using larger particles as delivery vehicles is that they are not cleared easily in vivo 
when compared to smaller particle formulations.   Despite these advantages, 
microparticles which sizes are larger than 2 μm cannot be use in our intraspinal injection 
experiment.  This is because when delivered by the nanoinjector system, these large 
particles suffered from sedimentation and clogged the needle tip resulting in low delivery 
efficiency of the particles. 
NR-PKMs, DiI-PKMs and coumarin-6-PKMs were used to evaluate the fate of 
PCADKe microparticles after intraspinal cord injection; however, only DiI-PKMs and 
coumarin-6-PKMs can be detected by fluorescent microscopy.  This might be due to the 
nature of the Nile Red since Nile Red only showed strong fluorescence in the lipid rich 
environment.  Although we didn’t observe the fluorescent signals from the Nile Red 
microparticles 3 hour after injection, we expect the released Nile Red might show 
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fluorescence when they diffuse out and contacted with cell membrane.  However, we still 
did not observe any fluorescent signal from the spinal sections obtained on day 3, day 7, 
day 14 and 1 month. 
Unlike NR-PKMs, DiI- and coumarin-6-PKMs showed a strong fluorescent signal 
in the spinal cord sections near the ventral horn, and this suggested we can deliver the 
microparticles to our targeted area using this intraspinal cord technique.  Since the DiI-
PKMs showed stronger fluorescent intensity than comarin-6-PKMs and their in vitro 
release profile also been studied as described in Chapter 2. DiI have been used as 
neuronal fluorescent tracers for CNS delivery (Krenz and Weaver 1998; Shibata-Iwasaki, 
Dekimoto et al. 2007; Liu, Li et al. 2008).  Therefore, DiI-PKMs were chosen to study 
the fate of the PCADKe microparticles after intraspinal cord injection.  The result showed 
that most of the DiI-encapsulated polyketal microparticles (DiI-PKMs) remained at the 
injection site after seven days which suggest that polyketal microparticles (1-2 μm) are 
not easily cleared in the neutral physiological environment and can have potential to 
continuously release drug from the injection sites in the spinal cord. 
 
AK-PKMs showed a trend toward improvement  
The efficacy of calpain inhibitor-encapsulated PKMs were studied by evaluation 
the behavior and survival of SOD1G93A rats. We observed the trend toward improvements 
in grip strength and rotarod performance in the first two months from the AK-PKMs 
treated group, however, there was no statistical differences between calpain inhibitor 
treated group with saline control.  The motor neuron assay showed that animals that 
received AK-PKMs have higher motor neuron density than the saline control and MDL-
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PKMs treated animals.  This result can explain the improvement of AK-PKMs treated 
group in the behavior study might contribute to the increase of motor neuron density in 
the spinal cord, however more animal numbers are required to get statistically 
differences.  We also calculated the mean area of motor neuron, but found no differences 
between any of the treatment groups.  The same phenomenon was also observed in the 
other ALS treatment study using intraspinal cord delivery technique (Franz, Federici et 
al. 2009).  
Several factors that may have accounted for the ineffective treatment such as, low 
calpain inhibitor dosage, diffusion problem of drugs and the timing for treatment were 
discussed to improve the future treatment. 
Due to safety consideration, the maximum volume of intraspinal cord injection is 
10 μL (5 μL, bilateral). To maximize the amount of particles can be delivered to the 
spinal cord, a high concentration of calpain inhibitor-loaded particles (50 mg/mL) were 
used in this study.  The total amount of drug loaded particles can be delivered to the 
spinal cord is 0.5 mg per rat.  The results of our in vitro experiment (Chapter 3, Table 
3.3) suggest that 24.48 ng (0.0485 nmole) of active AK295 or 1862.5 ng (4.87nmole) of 
active MDL-28170 was injected into each animal.  
The average weight of spinal cord is 560 mg, and the average length of the spinal 
cord is 10.5 cm.  Assuming that calpain inhibitor can diffuse 5 mm away from the 
injection site (10 mm in one direction) and 50 % of the drug is release in the first 30 days 
(from MDL-28170 in vitro release data in Chapter 3), the amount of calpain inhibitors we 
delivered to the spinal cord generate a total concentration of 0.455 μM of AK295 and 
45.55 μM of MDL-28170, and a daily concentration of 0.015 μM of AK295 and 1.522 
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μM of MDL-28170 in the first 30 day. Both total and daily concentration of AK295 
delivered to the spinal cord is lower than its IC50 value (1-14 μM of AK295), this might 
explain why we only observed little improvement from AK-PKM treatment.  The 
concentration of active MDL-28170 delivered to the spinal cord is 100 times higher than 
the concentration of active AK295, and both total and daily concentration of MDL-28170 
delivered to the spinal cord is higher than its IC50 value (0.01-1 μM of MDL-28170).  
However, we didn’t observe improvement from MDL-PKMs.  This might due to its BBB 
permeability and short half-life in circulation.   
Although current data doesn’t show a significant improvement of ALS treatment, 
they suggest that AK295-PKM has potential for future ALS treatment.  The future study 
should focus on improvement of AK295 delivery method, such as: enhancing the AK295 
encapsulation efficiency within the polyketal microparticles and increasing the injection 
volume by intrathecal injection technique.  One of the possible methods to improve the 
encapsulation efficiency is to use spray-drying technique to prepare AK-PKMs.  The 
spray-drying technique has shown to enhance the encapsulation efficiency of both 
hydrophilic and hydrophobic drugs in microparticles (Mu, Teo et al. 2005; Straub, 
Chickering et al. 2005; Piao, Kim et al. 2007; Guerrero, Muniz et al. 2008) therefore 
should be useful to improve the loading efficiency of AK295 in polyketal microparticles.  
The other method to enhance the dosage of the AK295 in the spinal cord is to increase 
the volume/amount of AK-PKMs that can be delivered to the spinal cord.  Currently the 
intraspinal cord injection technique is very invasive and only small volume (maximum 
at10 μL) of solution can be delivered by this technique.  Other less invasive injection 
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technique such as intrathecal delivery of AK-PKMs should be pursued in future 
improvement of AK-PKMs delivery. 
The transgenic rat model of ALS offer several advantages over existing mouse 
model of ALS, which may be limited in studies of drug disposition due to their size.  
However, the rat ALS model also is more variable than the mice ALS model.  A detailed 
discussion about the variability of rat ALS model was described by Matsumoto et al. 
(Matsumoto, Okada et al. 2006).  Suszuki et al. also reported that the onset of disease 
varied according to colonies and gender of SOD1G93A rat (Klein, Behrstock et al. 2005; 
Suzuki, Tork et al. 2007). Comparing our survival data with their data, our SOD1G93A rat 
showed slow disease progression (Suzuki, Tork et al. 2007).  The disease onset of our 
animal model was near 113 days, however, all the animals were treated around day 70. 
There is a 43 days difference between the treatment and disease onset.  Our in vitro data 
suggested very small amounts of calpain inhibitor were released at that time point.  This 
might be one of the possible reasons why we didn’t observe differences between 
treatment groups with the control group.  To solve this problem, we might need to treat 
the animal immediately after observation of disease onset.  And this treatment plan might 
be applicable since the patient already has symptoms when they began treatment.  
However, this treatment plan requires a more precise evaluation of the disease onset and 
might cause difficulties in the surgery schedule. 
In conclusion, we have demonstrated the development of a biodegradable 
microparticles delivery system for hydrophobic calpain inhibitors. Experiments using 
dye-encapsulated microparticles showed that polyketal microparticles (1-2 μm diameter) 
are not easily cleared in the neutral physiological environment and can have potential to 
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continuously release drug from the injection sites in the spinal cord.  We also observed 
the trend of improvement in the first two months in the AK-PKMs treated group, 
however, there was no statistic differences between calpain inhibitor treated group with 
saline control.  The low efficacy of AK295-loaded microparticles can be improved by 
enhancing the AK295 encapsulation efficiency and increase the amount of AK-PKM 
delivered via intrathecal injection.  We expect the improvements of AK-PKMs 
formulation and delivery method will deliver more AK295 into the spinal cord and thus, 





CONCLUSIONS AND FUTURE DIRECTIONS 
 
5.1 Conclusions 
In completing these specific aims, we have developed biodegradable polymeric 
microparticles for the delivery of calpain inhibitors to treat ALS. Using a new synthetic 
methodology, we synthesized a series of high molecular weight polyketal polymers, 
which can enhance the encapsulation efficiency of drugs and improve the structural 
stability of polyketal microparticles.  Based on one of the high molecular weight 
polyketals, PCADKe, we developed a polyketal microparticle delivery system which has 
a sustained release profile of a hydrophobic dye, DiI for one month, as a model delivery 
system for calpain inhibitors.  We demonstrated that the size of the particles is an 
important factor that affected the release rate and encapsulation efficiency of 
hydrophobic drugs in polyketal microparticles.  In general, smaller microparticles release 
drugs faster due to an increased surface area to volume ratio.  Based on these findings, we 
developed a polyketal microparticle delivery system for the calpain inhibitors, AK295 
and MDL-28170. The results of calpain assays showed that both AK-PKMs and MDL-
PKMs maintained most of their inhibitory activities even after the robust emulsion 
process.  The in vitro release profile of MDL-28170 in MDL-PKMs showed that 50 % of 
the drug was released in the first 30 days.  We also demonstrated that polyketal 
microparticles could be safely delivered to the spinal cord by using dye-encapsulated 
microparticles.  The results of the dye-encapsulated microparticle experiment showed 
that polyketal microparticles (1-2 μm) are not easily cleared in the neutral physiological 
environment and have potential to continuously release drugs from the injection sites. 
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The efficacy of calpain inhibitor-encapsulated PKMs were studied by evaluation of the 
behavior and survival of SOD1G93A rats, a genetic rat model for ALS.  We observed the a 
trend of improvements in grip strength, rotarod performance in the first two months for 
the AK-PKMs treated group, however, there was no statistical differences between 
calpain inhibitor treated groups with the saline control.  In summary, the results that 
polyketal microparticles have considerable potential as a delivery system for calpain 
inhibitor, however, further improvements are needed to enhance their in vivo efficacy.  
 
5.2 Future direction 
The efficacy of the current AK-PKMs can be improved by increasing the 
encapsulation efficiency of AK295, and the time for starting treatment.  We can also 
deliver other potential ALS therapeutics by using this polyketal microparticle delivery 
system. 
  
Prepare AK-PKMs by using a spray drying technique 
 We have shown that AK-PKMs can improve the grip strength, rotarod 
performance in the first two months even at low dosage of AK295 (24.5 ng per rat).  
Currently, the encapsulation efficiency of AK295 is around 2 to 17 % in PCADKe 
microparticles. Thus methods that could improve the AK295 encapsulation efficiency 
might benefit ALS treatment.  One of the possible methods to improve the encapsulation 
efficiency is to use the spray-drying technique to prepare the AK-PKMs.  The spray-
drying technique has been shown to enhance the encapsulation efficiency of both 
hydrophilic and hydrophobic drugs in microparticles (Mu, Teo et al. 2005; Straub, 
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Chickering et al. 2005; Piao, Kim et al. 2007; Guerrero, Muniz et al. 2008) and  therefore 
should be useful to improve the loading efficiency of AK295 in polyketal microparticles.  
The major limitation of this spray-drying technique is that we have to use a large quantity 
of the AK295 (500 mg) in a single experiment.   
 
Increase the amount of AK-PKMs delivered to the animals by using intrathecal 
injection technique 
The other method to enhance the dosage of AK295 into the spinal cord is to 
increase the volume/amount of AK-PKMs that can be delivered to the spinal cord. 
Currently the intraspinal cord injection technique is very invasive and only small volumes 
(maximum 10 μL) of solution can be delivered by this technique.  Intrathecal injection 
allows larger injection volumes and allows for repeated dosing (Svensson, Sottile et al. 
1991) since it is less invasive than intraspinal cord injection. In addition, intrathecal 
injection of therapeutics can provide a more diffuse therapy than intraspinal cord surgery 
since the therapeuticis are delivered into the cerebral spinal fluid (CSF), which bathes the 
whole spinal cord (Butler, Hayes et al. 2005).  The AK-PKMs or other therapeutic 
encapsulated polyketal microparticles, which are delivered by intrathecal injection, will 
serve as a depot for sustained release of AK295 and the other therapeutic agents to the 
spinal cord.  Furthermore, intrathecal injections, aka spinal taps, are a simple outpatient 






Start AK-PKMs treatment immediately after disease onset 
A large variation in disease progression of ALS rats has been reported (Klein, 
Behrstock et al. 2005; Matsumoto, Okada et al. 2006; Suzuki, Tork et al. 2007).  
Variations caused by litter and gender might affect the evaluation of the drug efficacy. In 
order to minimize the variation effect and evaluate the efficacy of the drugs accurately, 
we need to treat the animal immediately after the observation of disease onset.  This 
treatment plan might be applicable since ALS patient is symptomatic at the time of 
treatment. To achieve this, requires an accurate method to monitor the progression of 
ALS.  Matsumoto et al. demonstrated that pre-symptomatic disease onset can be 
identified by monitoring the peak body weight (Matsumoto, Okada et al. 2006).  The 
weight fluctuation in the animals is the main limitation for this method.  Recently 
Thonhoff et al. report a new method to detect slight motor deficits in the early stages of 
ALS by using a Photobeam Activity System (PAS) and wire mesh ascending test 
(Thonhoff, Jordan et al. 2007).  Combing these new evaluation methods with bodyweight 
measurement can potentially define the early signs of disease progression in ALS rats and 
allowing for treatment with AK-PKMs as soon as the disease onset is observed. 
However, this treatment plan requires increasing the workload in behavior study and 
might cause difficulties in the surgery schedule if too many animals showed disease onset 




Deliver other therapeutics using PCADKe microparticles for ALS treatment  
1) Rolipram 
Rolipram is an inhibitor of phosphodiesterase IV (PDE4; IC50= 0.8 μM).  Studies 
have shown that PDE4 is involved in the degradation of cAMP in motor neurons, thus 
delivery of Rolipram can increase the intracellular cAMP level and enhance the survival 
of motor neurons (Tomimatsu and Arakawa 2008).  Rolipram also has anti-inflammatory 
properties because it can enhance the level of norepinephrine which can suppress TNF-α 
(Ross, Williams et al. 1997).  Based on these properties, delivery of Rolipram might 
benefit ALS treatment.  The animal study done by the ALS Therapy Development 
Institute suggested that Rolipram can slightly improve the mean survival time of male 
ALS mice (ALS TDI website).  However, systemic delivery of Rolipram might cause 
dose limiting side effects (Rock, Benzaquen et al. 2009).  Therefore, drug delivery 
systems that can provide sustained release of Rolipram in the spinal cord have great 
potential in treating ALS.  Our preliminary studies showed that Rolipram can be 
encapsulated in PCADKe microparticles via single emulsion with a 2% encapsulation 
efficiency.  Further optimization of the Rolipram PKMs might be needed to generate 
desirable therapeutic effects on an ALS rat model. 
 
2) siRNA 
siRNA based therapeutics have tremendous potential to improve the treatment of 
human diseases.  Recently, several studies have been reported on the effect of siRNA on 
ALS therapy (Ralph, Radcliffe et al. 2005; Raoul, Abbas-Terki et al. 2005; Locatelli, 
Corti et al. 2007; Rizvanov, Mukhamedyarov et al. 2009), however delivering siRNA in 
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The hydrophobic ion paring technique has been used to encapsulate siRNA in 
polyketal nano- and micro-particles. TNF-α siRNA polyketal microparticles were shown 
to enhance the suppression of TNF-α level in RAW264.7 cells. In vivo studies also 
confirmed that TNF-α siRNA polyketal microparticles were effective in reducing liver 
damage and systemic inflammation in a mouse model of acute liver failure, as evidenced 
by decrease the serum level of TNF-α and alanine amionotransferase (ALT) (Sungmun 
Lee, manuscript submitted).  Based on these findings, we believe the use of polyketal 
microparticles for delivery siRNA in vivo will potentially benefit ALS treatment. 
 
3) Riluzole 
Riluzole (2-amino 6-trifluoromethoxybenzothizole) is an excitatory amino acid 
antagonist which specifically blocks NMDA, glutamate receptor and glutamate 
transporters (Couratier, Sindou et al. 1994; Estevez, Stutzmann et al. 1995).   Currently, 
riluzole (Rilutek®) is the only drug treatment for ALS approved by the Food and Drug 
Administration (FDA).  Dose limiting side effects are related to off-target effects of the 
medication including systemic and brain related symptoms.  Preliminary studies have 
demonstrated that intrathecal administration of riluzole did not cause neurotoxic effects 
(Sung, Lim et al. 2003). However, the proper dosage and immune response to intrathecal 
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riluzole has not been characterized. Besides riluzole has a dose-dependent 
neuroprotecitve effect on rat motor neurons.  Therefore, drug delivery systems that can 
provide sustained release of riluzole in the spinal cord might enhance the treatment 
efficacy of riluzole.  Our preliminary studies showed that riluzole can be encapsulated in 
PCADKe microparticles via a single emulsion solvent evaporation procedure.  Further 
characterization and optimization of the riluzole-PKMs might be needed to generate a 
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